pioneers 2006/2007 ANNUAL REPORT it Un en t & & r’s ct o ire D Th RI CM Ce Re Ce po ll ll B rt Tr io an Pg lo gy sfo 4 Un rm at it Ce io Pg ll n Si 6 U gn ni tP al G lin g Em en g 10 e b U ry Th ni ol t er Pg og ap M y y 12 U us Re ni cl se t e ar Pg D ch ev 14 el U op ni t m Pg en tU 16 ni t Pg 18 rc h id es Pr ea es rR RI M tC ou Ab Pg 2 s er ar Be ts s n or en ud St ffi ce O f& ct ire D tio isa an rg O af St e Pg Pg Pg Pg 26 24 22 20 { ce { { Ca n Our people Research Philosophy g in of ns tio la Re & Fu Re nd se ra – ar isi A ch ng fiv O e p Pg Ba ye er la Fu 34 ar at nc nd i an on e ra S al s he isi ys Re ng et is ve Su – Pg Al nu a m fiv lo e 36 m ca fr e ar tio om ye y ar n A Pg to ll an 36 S al Re o ys se urc i s ar e ch s & Pg 20 37 06 /2 00 7 D Pg Ho on w at 37 io Yo ns u Ca Pg n 38 He lp Pg 44 nd Fu ity m un m Co ns io ns ne ct io lic at Pg Pg 32 28 Thinking pioneers on Pu b lC ba lo G – F O R { ur { O International achievements C H I L D R E N E V E R Y W H E R E – Making it happen – C H I L D R E N ’ S M E D I C A L R E S E A R C H I N S T I T U T E – The Children’s Medical Research Institute (CMRI) was founded in 1958 to conduct research into childhood diseases. The basic philosophy then, as it is now, was that a deeper understanding of disease mechanisms would lead to better forms of treatment and, in many cases, to the prevention of diseases which cause premature death or long-term disability. Over the past 49 years, CMRI has contributed to advances in paediatric health and well-being in many ways, including the improved survival of premature babies, pioneering microsurgical techniques and developing paediatric heart and lung support systems for surgery in infants. More recently, the research efforts at the Institute have focussed on exploring the very basis of human development as a route towards understanding the molecular cause of disease. We have led the way in gaining new insights into the mechanisms of cancer, in basic studies on the development of the brain, nerve and muscle cells and their function, in working towards new gene therapies and in exploring the molecular mechanism for the establishment of the blueprint for embryo development. One in twenty children is born with a congenital abnormality or chronic condition. If we can determine the root cause of these problems, it may be possible to either correct or modify their effects. – – – – 2 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 3 A year of activity 2006/2007 This year saw a major event in the history of the Children’s Medical Research Institute with the retirement of Professor Peter Rowe on 24 July 2006. During his 26 years as CMRI’s Director, Professor Rowe shaped the Institute into a high-quality organisation that studies fundamental questions of human biology and disease. He assembled a first-rate team of scientists and the equipment and resources needed for their work. He has left behind an outstanding platform on which to build for the future. We wish him a very happy and fulfilling retirement. The transition to the post-Professor Rowe era has been smooth, and we greatly appreciate the efforts of all staff in this regard. In particular, we would like to highlight the work of two exceptionally talented staff members, Mr Stephen Ryall (Head of CMRI’s Administration and Community Relations) and Mr Greg Craig (CMRI’s Chief Operations Officer). Stephen worked with Professor Rowe throughout his 26 years with the Institute, and Greg for the majority of this time. Both have worked very effectively and with great adaptability to ensure a seamless transition. Among the many research successes this year, we would like to single out one for special mention. This is the discovery by Dr Scott Cohen in CMRI’s Cancer Research Unit of the molecular components of an enzyme called telomerase, that 85% of all cancers depend on for their continuing growth. Although researchers have known for many years that this is a critically important feature of cancer cells, no one has previously been able to obtain sufficient quantities of this enzyme to analyse it. Dr Cohen devised an ingenious strategy for extracting telomerase from cancer cells, and teamed up with members of CMRI’s mass spectrometry facility to identify its molecular subunits. This opens the way for the development of medicines that will treat cancer by blocking telomerase. This and other research highlights are described within the pages of this annual report. Our fundraising has also had an outstanding year. We particularly appreciate the commitment and hard work of our committees, who have raised a record amount this year. Bequests were also at a record high. Julijana Trifunovic and co-workers produced one of our best Jeans for Genes campaigns. CMRI’s scientists did particularly well in competing for grants from funding agencies such as the National Health and Medical Research Council of Australia (NHMRC). As a result, we have been able to fund our research, as well as adding substantially to CMRI’s endowment fund, which is critically important to our future. 4 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Throughout the year, we have enjoyed the support and commitment of CMRI’s Board. We are delighted that Mr Craig Knowles, former NSW Minister for Health, has recently become a Board member. The Board has completed the process of updating CMRI’s Constitution to bring Board membership into line with current best practice. A Board working group led by CMRI Vice-President Mrs Carolyn Forster negotiated a new agreement with the University of Sydney, and another working group led by Mr John Bevins formulated a strategic alliance with The Children’s Hospital at Westmead (CHW). We look forward to enhanced interactions with both of these important institutions, and we also appreciate excellent cooperative relationships with the other members of the Westmead Research Hub. The strategic direction being followed by the Children’s Medical Research Institute is based on the understanding that major advances in treatment and prevention of childhood diseases will come from discoveries about the fundamental processes of living cells and what goes wrong in disease. Given the outstanding resources that have been provided to us, it now seems to be the right time to redouble our efforts. Over the coming months, we will be making a detailed analysis of how we can do this. As we move forward, your support and encouragement will be appreciated more than ever. Frank Martin President Roger Reddel Director Hub of Activity – C M R I – Cell Biology Cancer Research – U N I T – – U N I T – Telomerase RNA in immortal cells Telomerase interaction with DNA Dynamin I inhibitory drugs for epilepsy and cancer Telomerase RNA in ALT cells Telomerase and G-quadruplex DNA Telomerase composition Dynamin and endocytosis Genes and proteins involved in ALT Dynamin II and cytokinesis IGFBP5 Turning ALT off Stanniocalcins Telomere erosion and DNA damage signalling Cell Signalling Mass spectrometry – U N I T – Prognostic implications of ALT YB1 and DNA damage signalling Telomere DNA in ALT cells p53 and ALT in glioblastoma Transgenic/knock-out mouse technology Nemaline myopathy and therapies Dynamin II in cancer p53 and DNA damage signalling p53 blocks cancer in mice Fate mapping – endoderm Liver-directed gene therapy Muscle and type II diabetes Rett syndrome and Mecp2 gene – U N I T – Vectors for haematopoietic disease/SCID-X1 Williams syndrome and human behaviour Mouse models of muscle disease Cell Transformation Craniofacial development Gene function in the endoderm Immune tolerance in vaccine development Stem cell therapy for muscle disease (CHW) Development of Human Applications Laboratory (CHW) Gsc and Dkk1 in head formation Eye genetics Muscle Development – U N I T – Gene therapy for chemoprotection in paediatric brain tumour treatment (CHW) Embryology – U N I T – Gene Therapy Research – U N I T – – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 5 A giant leap forward DR COHEN DEVISED AN INGENIOUS STRATEGY FOR EXTRACTING TELOMERASE FROM CANCER CELLS. THIS OUTSTANDING DISCOVERY Cancer Research (an international first) – U N I T – OPENS THE WAY FOR THE DEVELOPMENT OF MEDICINES THAT WILL TREAT CANCER BY BLOCKING TELOMERASE. Telomerase composition 6 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Working together – C A N C E R R E S E A R C H U N I T & C E L L UNIT HEAD, ROGER REDDEL What we do Cancer cells are so similar to our normal cells that it has been hard to find cancer treatments that leave healthy cells untouched. The Cancer Research Unit and Cell Biology Unit are investigating a key characteristic of cancer cells that distinguishes them from normal cells – the ability of cancer cells to go on multiplying an unlimited number of times – they are ‘immortalised’. If we can find treatments that target this property, they are likely to have far fewer side effects than currently available chemotherapies. Every time normal cells multiply, the telomeres, the DNA at the ends of the chromosomes, shorten slightly. Eventually, the telomeres become critically short, signalling to the cell to stop multiplying. This is an important built-in barrier against cells becoming ’immortal’. Cancer cells breach this barrier by activating a mechanism to prevent telomere shortening. The majority of cancers do this using an enzyme called telomerase, which is not present in most normal cells in the body, and therefore drugs that block telomerase could provide a specific therapy for cancer. A minority of cancers use another mechanism called Alternative Lengthening of Telomeres (ALT). Drugs to block ALT will be required for these tumours and for telomerase tumours in the event that they switch to ALT to evade telomerase blocking drugs. The Cancer Research and Cell Biology Units are investigating both telomerase and ALT with the aim of discovering ways to block these mechanisms and so directly attack cancer cell immortality. Cancer Research Unit Achievements We have been investigating which genes and proteins are involved in the ALT mechanism. These analyses have previously been very time consuming, but Dr WeiQin Jiang and colleagues have now devised a relatively rapid method and have successfully used it to identify eight proteins that are likely to be important for ALT. Cells that use the ALT mechanism are unusual because they contain a large quantity of telomere fragments that are no longer attached to chromosome ends. Dr Clare Fasching, Dr Alessandra Muntoni and their co-workers have been studying what happens to these detached telomeres in order to obtain clues as to the nature of the ALT mechanism itself. B I O L O G Y U N I T – UNIT HEAD, TRACY BRYAN Does it matter to patients whether their cancers use ALT or telomerase? We’ve been studying this together with colleagues in CMRI’s Cell Transformation Unit and colleagues in Italy, New Zealand and at the Kolling Institute in Sydney. Patients with one type of cancer, liposarcomas, do worse if they have ALT. Patients with the most common form of tumour arising in the brain, glioblastoma, have a much better life expectancy, however, if their tumours have ALT. These tumours are also much more likely to have mutations in the tumour supressor gene p53. So this is a rare situation in which the presence of p53 mutations is a favourable indicator. Highlights During the past year, we completed a three-year project to identify the molecular components of telomerase. Telomerase was first found in human cancer cells in 1989, and it had become very clear by 1994 that it was an important feature of most human cancers. However, despite major efforts in many laboratories around the world, it had proved impossible to precisely identify its molecular subunits. This is because telomerase is present in such tiny quantities in cancer cells that no one could obtain sufficient quantities for analysis. Using various indirect methods, researchers identified 32 proteins that they thought were molecular subunits of telomerase. To obtain the definitive answer, Dr Scott Cohen in CMRI’s Cancer Research Unit enlisted the help of Dr George Lovrecz, at the CSIRO in Melbourne, to grow large quantities of cancer cells in a bioreactor. He also devised an ingenious scheme for extracting telomerase out of all of the other substances within cells. Then, with the help of Drs Mark Graham, Nicolai Bache and Phillip Robinson from CMRI’s Cell Signalling Unit, he used our mass spectrometry facility to precisely identify the telomerase subunits. Dr Cohen found that in fact telomerase has only two protein subunits. We now know, for the first time, the molecular components of the enzyme that is critically important for the growth of 85% of all human cancers. The future These are all major steps forward in cancer research. We intend to capitalise on this progress over the next year to move closer to the goal of being able to design anti-cancer treatments based on blocking ALT and telomerase. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 7 Telomerase RNA in immortal cells Telomerase RNA in ALT cells Cancer Research Telomerase composition – U N I T – Telomere erosion and DNA damage signalling Genes and proteins involved in ALT Turning ALT off Prognostic implications of ALT Stanniocalcins Telomere DNA in ALT cells Process & Discovery 8 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Telomerase and G-quadruplex DNA OUR EXPERIMENTS WERE MADE POSSIBLE by a surprising (AND EXCITING) chance discovery OF A REMARKABLY STABLE VARIETY OF Cell Biology G-QUADRUPLEX DNA. – U N I T – Telomerase interaction with DNA Discovering options – C A N C E R R E S E A R C H Cell Biology Unit Telomerase is a very specialised and unique enzyme, and there are many gaps in our knowledge of how it works. This makes it a fascinating enzyme to study, revealing the complexity of the machinery inside cells. It also means that we have much to learn before we can design rational telomerase inhibitors to treat cancer. The Cell Biology Unit has been investigating some fundamental questions about how telomerase interacts with telomeric DNA. Highlights and achievements DNA is normally recognised as the classic double helix structure; however, the DNA located at telomeres appears to fold into some unusual structures; for example, a four-stranded structure known as a G-quadruplex. It was previously thought that telomerase is unable to extend G-quadruplexes; this folding of the telomere was hypothesised to be one way that the cell controls telomerase action. It was hoped that this property could be exploited to develop a class of telomerase inhibitors that ‘lock’ G-quadruplexes in place, thus blocking telomerase access. Unexpectedly, we found that telomerase is able to extend a sub class of G-quadruplex structures. This means that more work is needed to determine which type of G-quadruplex is present in cells, and whether the drugs are always able to block telomerase. Over the last year, we have been further characterising this unexpected property of telomerase. We found a mutation of telomerase that made it unable to extend G-quadruplexes, while its ability to extend ‘linear’ DNA was unaffected. This indicates that telomerase may have evolved the ability to deal with these two types of DNA in a different manner, increasing the chances that our ‘test-tube’ discovery does reflect the situation in living cells. The telomerase we have used for these studies is from a one-celled pond creature called Tetrahymena. This organism can be easily genetically manipulated (unlike human cells), so we will be able to introduce the same telomerase mutation into living cells. We can then investigate why telomerase would need to extend G-quadruplexes, and what implications this has for the ability of cells to multiply. U N I T & C E L L B I O L O G Y U N I T – These experiments were made possible by our chance discovery of a particularly stable variety of G-quadruplex DNA. We determined the structure of this G-quadruplex using the CMRI mass spectrometry facility; normally this machine is used to identify proteins, but with the expertise of Drs Mark Graham and Phillip Robinson of the Cell Signalling Unit, we were able to adjust the machine to enable it to deal with DNA molecules. One of the unique properties of telomerase is its ability to add multiple ‘blocks’ of DNA to the telomere in a repetitive manner. It does this using a ‘racheting’ motion, with several parts of the enzyme maintaining contact with the DNA throughout the process. The number and location of these DNA ‘anchor sites’ has been the subject of much investigation, since they may represent one avenue to block telomerase from accessing the telomere. In the telomerase field, this research has been hampered by technical difficulties in producing large amounts of the enzyme. We have successfully developed a way to quantitatively measure the interaction of telomerase and DNA using very small amounts of enzyme. This has enabled, for the first time, an evaluation of the relative contributions to DNA binding of different regions of the enzyme. We found that there are a minimum of four DNA-binding sites and that together these enable telomerase to bind very tightly to telomeric DNA, explaining its ability to maintain contact with the telomere. Since our technique is quantitative, we found that a region previously implicated by others in binding to telomeric DNA actually contributes only minimally to DNA binding. Our data also suggest that different DNA binding sites are used during different stages of the addition cycle, adding to the complexity of what is known about telomerase mechanisms. The future There is a constant exchange of techniques and biological insights between the Cell Biology and Cancer Research Units. The recent exciting work of the Cancer Research Unit on the identity of the molecular subunits of telomerase will greatly enhance progress in the Cell Biology Unit in the coming year. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 9 Finding the new – C E L L UNIT HEAD, ANTONY BRAITHWAITE T R A N S F O R M A T I O N U N I T – OUR RESEARCH WILL BE ENORMOUSLY HELPFUL FOR PATIENT PROGNOSIS AND FOR DECIDING UPON THE MOST EFFECTIVE TREATMENT. CELLBANK AUSTRALIA Cultured cells – grown in plastic flasks or dishes outside the body – are an excellent model for the study of disease processes because they allow the researcher to focus on a single cell type. However, cultured cells are vulnerable to contamination by micro-organisms and other, faster growing cell populations. Researchers can avoid such contamination by obtaining their cells from a repository or cell bank. To date, these repositories have been located outside Australia and can be difficult to access. CellBank Australia is a new repository which will offer cultured cell lines to scientists around Australia. These cell lines are collected from researchers, checked for contamination and made available to other researchers on a cost recovery basis. Over the last year, we have completed construction of the facility and worked on its quality control. The facility is now open for cell line deposits. The Lady Mary Fairfax CellBank Australia was established by a joint venture of the Children’s Medical Research Institute, Cure Cancer Australia Foundation, and the National Breast Cancer Foundation, and by an Enabling Grant of the National Health and Medical Research Council. The facility has been operated by CMRI since July 2007. 1 0 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – p53 and ALT in glioblastoma p53 and DNA damage signalling Dynamin II in cancer YBI and DNA damage signalling p53 blocks cancer in mice How p53 works and how p53 receives the signals to carry out its role in the cell, are the principal areas of research in the Cell Transformation Unit. diagnosis. Being able to separate these GBM subtypes will be useful for patient prognosis and for deciding upon the best treatment. Our goal is to find ways of distinguishing these different kinds of GBM. To do this, we are collaborating with the Cancer Research Unit and colleagues at the University of Otago, New Zealand (NZ). We have shown that a mutated P53 gene is able to distinguish one group of patients with better survival prospects than those with a normal P53 gene. This is an unusual finding, as mutated P53 genes are often found in advanced cancers. Further investigation has shown that this mutant P53 associates with the ALT telomere maintenance mechanism, discovered at CMRI some years ago. ALT has also been previously found to be associated with better patient prognosis in GBM, a discovery also made at CMRI with our NZ colleagues. From our recent findings, therefore, we speculate that mutant P53 favours the acquisition of ALT and hence explains why it is associated with better prognosis. Achievements Highlights One currently exciting line of research addresses the question of how p53 prevents us from getting cancers. To find this out we have created a genetically modified mouse in which the P53 gene is altered so that its protein product is unable to kill cells. We have investigated whether these mice are susceptible to cancers, as we know that similar mice with no P53 gene develop lots of cancers. We have found that the mutant p53 in the cells of this mouse is indeed unable to cause cell death in response to DNA damage. It also appears to be unable to temporarily stop cells growing. However, the mice so far have not developed cancers. These results indicate that p53 prevents cancers forming, not by stopping cells growing nor by killing cells, but by a different process. We will be investigating this further in the coming year. In our first full year here at CMRI, we have grown from a staff of three to our current nine. What we do The P53 gene is present in all cells in our bodies and encodes a protein of the same name, p53. Without p53 we get cancers. p53 is produced in extremely small amounts in most cells; however, if the DNA in these cells becomes damaged, for example through mistakes in copying the DNA when a cell divides, exposure to carcinogens, or by telomere shortening, p53 levels rise. p53 then does some drastic things to cells – it kills them, stops them growing temporarily, or stops them growing permanently. This is called senescence – a cellular aging process. Many people think that causing one of these processes to occur, in particular cell death, is how p53 prevents cancers from forming. We have also focussed on a human brain cancer called glioblastoma (GBM). Although not common, GBM is almost always fatal in adults. One problem in understanding GBMs is that they are not all the same; groups of patients have different survival times after The future A new line of investigation has also commenced recently in collaboration with the Cell Signalling Unit. They recently discovered that dynamin II, a protein required for pinching off little vesicles (bags containing neurotransmitters) in nerve cells, may carry out a ‘pinching’ role in cell division. Once the chromosomes of cells have divided, they separate to opposite poles of the cell and slowly pull away from each other, eventually breaking off to form two daughter cells. This process is known as mitosis. Dynamin may be involved in the final step of mitosis, known as cytokinesis, clipping apart the two cells like a pair of scissors. The two Units are working together to investigate this process, as p53 is a well-known player in regulating cell division processes. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 1 1 Leading research UNIT HEAD, PHILLIP ROBINSON – C E L L What we do The Cell Signalling Unit is unravelling the mechanisms that underlie two important diseases – epilepsy and cancer. Cells need to talk to each other and pass internal messages to carry out their function (for example growth or cell division). The message is passed by protein-protein interactions or by proteins modifying other proteins. We call this cell signalling. Genetic disease can disrupt the line of communication and so disrupt the work of a cell. Central to cell signalling is the protein dynamin. Dynamin I is only found in the brain, while dynamin II is found in all cells. Epilepsy is a disease of nerve communication (synaptic transmission). It affects around 1% of Australians. Symptoms usually appear during childhood and seizures may be managed by anti-epileptic drugs. However, up to 30% of children don’t respond to currently available drugs. We are investigating proteins like dynamin I that are required for nerve communication and which control neuronal excitability. Cancer is also a disease of defective cell signalling that allows cells to escape the normal controls that regulate cell growth and division. We are investigating proteins like dynamin II to determine their possible role in cancer. Highlights We made discoveries about the molecular machinery underlying synaptic transmission. Last year, we found that two main phosphorylation sites in dynamin I control binding to a partner protein, syndapin. This year, we mapped the binding site involved in their interaction and found a further five phosphorylation sites, suggesting new functions for each of them. We also mapped every phosphorylation site in the other major proteins that are involved in synaptic transmission (synaptojanin, amphiphysin and AP180). Understanding the role of phosphorylation in these proteins is important because they are all linked to sustaining synaptic transmission, which is required for a seizure to spread. Our team has also been studying the final stages of cell division that allow the cells to finally separate – cytokinesis. We found new proteins involved in the process and identified that dynamin II is essential for cytokinesis. The implications are that cancer might be treated in the future by inhibiting dynamin II and preventing cancer cells from completing division. 1 2 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – S I G N A L L I N G U N I T – Dr Megan Fabbro, who is leading this program, was awarded the Young Cancer Researcher of the Year Award from the Cure Cancer Australia Foundation. In collaboration with scientists at the Royal North Shore Hospital, we have been studying the protein IGFBP5. This protein circulates in blood and regulates growth of various tissues. It is also elevated in some cancers. We found the phosphorylation sites for this protein and are endeavouring to better understand its role in cancer. We also used our mass spectrometry expertise to assist the Cancer Research Unit in identifying the composition of the telomerase enzyme. Major achievements of the year Blocking dynamin I may lead to new types of antiepileptic drugs while blocking dynamin II may lead to new anti-cancer drugs. This year, we commenced a joint program with the National Institute of Health Anticonvulsant Screening Program in the USA to test representatives of the best dynamin-blocking drugs we have developed in conjunction with medicinal chemists at the University of Newcastle. The outcome will allow us to establish the principle that dynamin I inhibitors are a good anti-epileptic target and help define which drugs should be further developed. We have already shown that the MiTMAB series of drugs can block synaptic transmission in a laboratory test. All current anti-epileptic drugs reduce synaptic transmission by dampening it down a few percent, 24 hours a day. A dynamin inhibitor acts via a different mechanism and would represent a potentially new class of anti-epileptic drug. It should only reduce synaptic transmission when it is elevated to a very high level; preventing the build-up to, and spread of, a seizure. The future The drug discovery program will be a major focus over the next 12 months. The outcome of the animal tests of the anti-epileptic drugs will also determine the potential for a similar anti-cancer screening program. Cutting-edge technologies underpin the basic science beneath all projects within our group and other CMRI Units and keep us at the forefront of medical science. The mass spectrometry facility is a prime example of this and we hope to expand it in the coming year to boost throughput and sensitivity. The application of robotics and the new ImageExpress fluorescent microscope will help with faster assays and screening of anti-epileptic and anti-cancer drugs. major advances in science Mass spectrometry Dynamin II and cytokinesis THE FACILITY IS USED EXTENSIVELY Dynamin I inhibitory drugs for epilepsy and cancer WITHIN CMRI AND IN COLLABORATION WITH SCIENTISTS AND INDIVIDUALS Dynamin and endocytosis from around the world IGFBP5 MASS SPECTROMETRY AND FUNCTIONAL PROTEOMICS FACILITY (MSFPF) Mass spectrometry is the most rapid and sensitive approach available for protein identification and characterisation. The MSFPF at CMRI, managed by the Cell Signalling Unit, currently has two mass spectrometers (MALDI-TOF and quadrupole-TOF). It is a collaborative research resource that combines applied proteomics with the development of new and improved methods for protein identification and characterisation. The facility is used extensively within CMRI and in collaboration with scientists from the Westmead Research Hub and individuals from around Australia and the world. This year, the Facility has contributed to major advances in neuroscience, cancer and muscle disease research. Within the Cell Signalling Unit, we have completed a body of work on the phosphorylation of all the proteins involved in synaptic vesicle endocytosis. It provided a final crucial step in the identification of the components of human telomerase made by the Cancer Research Unit of CMRI. A major collaboration with Professor Kathryn North of The Children’s Hospital at Westmead has revealed clues to the genetic mechanisms behind two childhood muscle weakness disorders. In the next year, the Facility is set to increase its capacity with further specialist mass spectrometry staff and new instruments. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 1 3 Exploring development – E M B R Y O L O G Y UNIT HEAD, PATRICK TAM U N I T – grow and live a healthy life UNDERSTANDING THE COMPLEX PROCESS OF DEVELOPMENT, AS WELL AS MALFUNCTIONS THAT CAN RESULT IN SERIOUS COMPROMISE OF QUALITY OF LIFE FOR CHILDREN OR THEIR FAMILIES. Transgenic/knock-out mouse technology grow Fate mapping – endoderm grow Rett syndrome and Mecp2 gene Craniofacial development Gene function in the endoderm Gsc and Dkk1 in head formation 1 4 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Eye genetics What we do The objective of our research program is to understand the process of normal embryonic development and to establish how faults leading to birth defects may arise. We began by tracking the developmental fate of cells in the early embryo, at a stage well before any visible body parts can be recognised, a process known as fate-mapping. The aim was to ascertain if there is a blueprint – a predetermined arrangement of cells to generate the various tissues and organs of the embryo. To do this, we pioneered techniques which involve tracking the differentiation of marked cells and their descendants in mouse embryos grown in culture. Our research has progressed from studying the formation of the germ layers (the building blocks) to encompass the stage of organogenesis (the formshaping process). This period of development in the mouse corresponds to the first eight weeks of human embryonic life, when any error in development could result in serious malformations that impact on quality of life for children and families. We have focussed on the head, face and jaws, and the eyes. We also study the developmental basis of Rett syndrome – a debilitating neurological condition associated with mutations in the Methyl-CpG-Binding Protein 2 (MECP2) gene which accounts for up to 10% of all profound intellectual disability in females. The Eye Genetics Group is seeking genes responsible for congenital eye defects – cataracts, glaucoma, anophthalmia (no eyes) and microphthalmia (small eyes) – in order to find novel treatments for these conditions. Highlights and achievements For over a decade we have systematically examined the fate maps of different germ layers of the mouse embryo: starting with the outer layer that generates the skin and the nervous system (the ectoderm); followed by the middle layer that produces the muscle, bone and other supporting tissues (the mesoderm). Our project reached a major milestone in 2007 with the near completion of the fate map for the last germ layer, the inner layer (the endoderm) which forms the digestive tract. Our group has identified a set of genes – some of which were previously unknown – and the components of signalling pathways that enable cells to communicate with one another during formation of the gut. We have developed an expeditious strategy to determine the function of a gene using mouse embryonic stem cells in which the activity of a gene has been altered. With this technique, a whole embryo can be generated completely from these stem cells allowing a rapid preliminary study before commencing the lengthy production and analysis of genetically modified mouse models. We have already used this approach to investigate the function of several genes that are expressed by endoderm cells. Our expertise in the production of transgenic, knockout and chimeric mice has also contributed to the work of other Units within CMRI and external collaborators. Recently we discovered the interaction of two genes (Gsc and Dkk1) in head formation – loss of these genes in mice led dramatically to a loss of the head due to disruption of a signalling pathway. Our Eye Genetics Group identified a novel gene in cataract development. They achieved this by studying a family with a break in their chromosomes which helped pinpoint the location of the gene. Significant progress has been made in the characterisation of a genetic mouse model for Rett syndrome. We have identified changes in gene activity in the brain that reflect the progression of the disease and accompany the loss of behavioural function. The future After the completion of the fate-maps, the next challenge is to capitalise on our embryological expertise to visualise the dynamic process of embryonic development. Digital imaging techniques will be used to follow the movements of cells, and the accompanying changes in shape of tissues, as the embryo develops. This will provide a comprehensive illustration of how the blueprint is translated into a whole embryo. We are building several mouse models with a mutation in the Twist1 gene for studying the human condition Saethre-Chotzen Syndrome (SCS), which is characterised by abnormal skull and facial morphology. In these mice, the Twist1 gene is specifically switched off in cranial neural crest cells to determine how loss of neural crest cells affects craniofacial development in SCS. The Eye Genetics Group will identify new disease genes through clinical investigations and explore several animal models for genes associated with congenital eye defects. We aim to discover therapeutic targets for Rett syndrome through a collaboration with clinical geneticists at The Children’s Hospital at Westmead and a team at the University of Sydney. We will undertake parallel clinical genetic investigation and animal model studies of two novel genes that have a potential link to the Mecp2 gene and may be related to other X-linked neurological disorders. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 1 5 Vectors for haematopoietic disease/SCID-X1 Liver-directed gene therapy Immune tolerance in vaccine development Development of Human Applications Laboratory (CHW) Gene therapy for chemoprotection in paediatric brain tumour treatment (CHW) This is a tremendously exciting Gene Therapy Research – U N I T – but challenging area of research. 1 6 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Promising results – G E N E T H E R A P Y R E S E A R C H U N I T – UNIT HEAD, IAN ALEXANDER THE ONGOING CHALLENGE FOR THE GENE THERAPY RESEARCH UNIT IS TO TAKE OUR MOST PROMISING LABORATORY RESULTS FORWARD TO HUMAN CLINICAL APPLICATION. THIS IS NOT A JOURNEY FOR THE FAINT-HEARTED, AND IS THE CENTRAL MISSION OF THE UNIT. What we do The Gene Therapy Research Unit, a joint initiative with The Children’s Hospital at Westmead, is focussed on the development of novel gene-based strategies for the treatment of genetic conditions affecting children. This is a tremendously exciting but challenging area of research requiring both laboratory and clinical expertise. The liver and bone marrow are two particularly promising targets for gene therapy, as many childhood genetic diseases involve these tissues. The key challenge of gene therapy is to safely repair or replace faulty genes with healthy ones in a sufficient number of cells to achieve therapeutic benefit. Our approach involves the use of cutting-edge gene delivery technologies (vectors) derived from viruses. The long but immensely rewarding journey towards human therapy begins with genetic repair of isolated cells growing in cell culture using this technology. It can then progress to the treatment of disease in small animals such as mice. Highlights In the last year, we have successfully treated mice with two different genetic conditions: X-linked Severe Combined Immune Deficiency (SCID-X1) by genetic repair of bone marrow cells; and a urea cycle defect, Ornithine Transcarbamylase (OTC) deficiency, by genetic repair of liver cells. The studies on mice with SCID-X1 are focussed on enhancing the safety of gene transfer and are part of our ongoing international collaboration to treat children with this condition with world leading paediatric hospitals in Paris and London. Based on the exciting success in mice with OTC deficiency, we are now also planning to work towards clinical trials for children with urea cycle defects. This goal will require substantial effort over a number of years to be realised. Another extremely promising result obtained in the last year is the discovery of a strategy to selectively block unwanted immune responses that could otherwise interfere with effective gene therapy in a diverse range of applications. On the clinical front we are continuing to work towards a trial aimed at improving the treatment of children with brain tumours. Our intent is to use gene transfer to increase the resistance of bone marrow cells to the damaging effects of chemotherapy. If successful, this will not only reduce the side effects of conventional treatment, but also allow higher and potentially more effective doses of chemotherapy to be given. This effort, being undertaken in collaboration with the Oncology Unit in The Children’s Hospital at Westmead, demands that we successfully confront complex translational challenges. These include the commissioning of a specialised human applications laboratory (HAL), based in The Children’s Hospital at Westmead, the generation of clinical grade vectors for gene delivery, the development of assays to monitor safety and efficacy, and the completion of regulatory documentation and clinical trial protocols. Our current aim is to initiate this trial during 2008. Achievements While the past year has been particularly productive and exciting, one particular highlight was the publication of our research findings in the prestigious Journal Blood. We showed for the first time that partial deficiency of the gamma-c gene, which is faulty in infants with SCID-X1, differentially affects the development of specialised cells within the immune system. This finding not only offers insights into the development of the immune system, but also has important implications for the improved design of gene transfer vectors for SCID-X1 gene therapy. The future The ongoing challenge for the Gene Therapy Research Unit is to take our most promising laboratory results forward to human clinical application. This is not a journey for the faint-hearted, and is the central mission of the Unit. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 1 7 Research for all people – M U S C L E D E V E L O P M E N T U N I T – UNIT HEAD, EDNA HARDEMAN Stem cell therapy for muscle disease (CHW) Nemaline myopathy and therapies What we do The Muscle Development Unit is engaged in a range of research activities aimed at understanding the basis for specific muscle diseases, trialling therapies, characterising novel protein structures that we discovered in muscle and defining their roles in muscle disease and type II diabetes. We are also studying how one gene, discovered in the Unit, Gtf2ird1/MusTRD, can profoundly affect skeletal muscle and yet also play a role in the brain. Our approaches span from bench to bedside. Human muscle diseases share common features which can include weakness, repair of damaged muscle cells, alterations in the size of muscle cells (hypertrophy or atrophy) and changes in the relative numbers of fasttwitch and slow-twitch muscle cells. In addition, most of these features of muscle disease are also found in normal muscle adapting to new usages and can occur during ageing. Therefore, our findings will benefit not only individuals who suffer from muscle disease, but those who suffer muscle or motor neuron damage, athletes and the normal ageing population. Highlights A major focus of our work over the past 10 years has been to investigate childhood muscle diseases, to define mechanisms of disease traits and more recently 1 8 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Mouse models of muscle disease Williams syndrome and human behaviour Muscle and type II diabetes to trial therapies. We successfully generated a mouse model for the major congenital muscle disease, nemaline myopathy by engineering a mutation in the α-skeletal actin gene found in human patients. We are testing potential therapeutic strategies on these mice alongside trials that are being conducted by Professor Kathryn North on children at The Children’s Hospital at Westmead, with very promising results. Dystrophies are diseases in which muscle is chronically damaged and repaired because of a defective gene. We have devised a unique method of providing genetically corrected muscle stem cells with a selective survival advantage when introduced into dystrophic muscle. This is a novel application of a selective cell enrichment strategy, initially established for haematopoietic cells, which allows the genetically corrected stem cells to out-compete diseased stem cells, leading to the replacement of diseased muscle with normal muscle. We are collaborating on this with Professor Peter Gunning and Dr Geoff McCowage of the Oncology Unit, The Children’s Hospital at Westmead, using tools generated by the Gene Therapy Research Unit. We discovered a new protein scaffold in muscle cells involved in the movement of the GLUT4 molecule that transports glucose into muscle cells. Defects in glucose uptake in skeletal muscle are a major contributing OUR RESEARCH BENEFITS ALL PEOPLE from the very young TO ATHLETES AND THE AGEING POPULATION. factor in the development of type II diabetes. In collaboration with Professor Peter Gunning, The Children’s Hospital at Westmead, and the Diabetes and Obesity Research Program at the Garvan Institute, we are defining the function of this novel protein scaffold in glucose homeostasis. This potentially provides a new target for treatment of diseases of altered glucose clearance, including type II diabetes and obesity. and behaviour. In early 2007, we were awarded an NHMRC grant to investigate the role of Gtf2ird1/ MusTRD in aspects of behaviour. We have determined, using genetically modified mice that are lacking this gene, that Gtf2ird1/MusTRD plays a role in regulating sociability and anxieties. We have also found that controlling Gtf2ird1/MusTRD activity may provide a means to control seizures. A number of years ago, we first identified a novel family of proteins encoded by the gene Gtf2ird1/ MusTRD when looking for proteins that could alter the composition of fast or slow-twitch muscle cells in a muscle. We have found that forced expression of the MusTRD proteins in the muscles of mice can profoundly change the relative numbers of fast-twitch and slow-twitch muscle cells and hence, these proteins may provide a means to alter fibre type composition in muscles affected by nerve damage and disease. The future Achievements Gtf2ird1/MusTRD lies within a block of genes commonly deleted in the neurodevelopmental disorder Williams syndrome (WS). WS is characterised by specific neurological and cognitive defects with a unique personality profile. There is much interest in WS because the neurological and cognitive changes reveal a genetic basis for aspects of human cognition The most exciting prospects for the near future are the therapies that we are developing for nemaline myopathy and muscle diseases such as the dystrophies. With our nemaline mouse model, not only are we close to defining a therapy that can alleviate impaired mobility, but will also explain the mechanism behind it. We anticipate that the next stage for the muscle stem cell therapy will be as a means to improve the performance of specific muscles in dystrophy patients, with the goal to improve quality of life. Our close relationship with The Children’s Hospital at Westmead will result in the translation of our findings into clinical trials. The mouse models we have generated allow us to identify the best potential treatment strategies for patients. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 1 9 Grants Advisory Committee Chairman, P Robinson Investment and Finance Committee Board of Directors Chairman, R Atfield President, F Martin Internal Communications Committee Convenor, R Hardman Audit and Risk Committee Chairman, R Atfield Occupational Health and Safety Committee Chairman, K Steiner Bioservices Management Committee Chairman, G Craig Animal Care and Ethics Committee Co-Chairs, P Tam and I Alexander Intellectual Property Committee Chairman, F Martin Institutional Biosafety Committee Chairman, R Reddel Scholarships Committee Acting Director R Reddel Chairman, T Bryan The organisation – T H E 2 0 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – C M R I T E A M – Jeans for Genes Executive Committee Jeans for Genes Staff Voluntary Fundraising Committees Administration and Appeals Staff National Campaign Manager, Jeans for Genes Office Manager K Ritson Science Communication Staff J Trifunovic Accounts Staff CellBank Australia Staff Bioservices Staff Manager, Administration and Community Relations and Company Secretary Community Relations Officer S Ryall J Philps Manager, CellBank Australia A Capes-Davis Accountant Manager, Bioservices J Mullin I Villaflor Operations Staff Manager, Operations G Craig Research Staff Head, Gene Therapy Research Unit I Alexander Research Staff Head, Cell Transformation Unit A Braithwaite ICT Staff Research Staff Manager, Information and Communications Technology D Capes-Davis Research Staff Head, Embryology Unit P Tam Mass Spectrometry Facility Manager V Valova Head, Cell Signalling Unit P Robinson Research Staff Research Staff Head, Muscle Development Unit E Hardeman Head, Cell Biology Unit T Bryan Head, Cancer Research Unit Research Staff R Reddel – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 2 1 Associate Professor Frank Martin MBBS FRANZCO FRACS AM OPH, President Frank Martin is Head, Department of Ophthalmology, The Children’s Hospital at Westmead, and a Visiting Ophthalmologist at the Sydney Eye Hospital. He served on the International Council of Ophthalmology from 1998 to 2006. He remains a member of the Council of the Asia Pacific Academy of Ophthalmology and is on the Board of the Lowy Medical Foundation. He is also Chairman of the Westmead Research Hub Council. Frank has been a CMRI Board member since 1986 and was elected President in April 2000. Mr John Bevins Mrs Carolyn Forster OAM, Vice President Carolyn Forster has been a member of the Canberra Committee of CMRI since 1973, serving twice as President and twice as Treasurer. She has worked in the Federal Parliament for eleven years, in the Senate, the House of Representatives, and the Ministry. She has chaired the ACT Heritage Festival for eleven years, chaired the Board of Phillip College and was a past President of the Women’s International Club, ACT. Carolyn is currently President of the Friends of the National Museum of Australia, President of the Australian Federation of Friends of Museums, Chair of the Church of St Andrew Conservation and Restoration Foundation, as well as serving on a number of other committees. She received an ACT Women’s Award in 1996, a Centenary Medal in 2003, and an OAM in 2006. Carolyn joined the Board in 1996 and was elected Vice President in 2000. Mr Rodney Atfield FIA FIAA FAII, Treasurer Rodney Atfield was formerly the Managing Director of the Mercantile Mutual (now ING) group of companies and was Chairman of QBE/Mercantile Mutual Limited. He is an actuary by profession and is a former President of the Institute of Actuaries of Australia and has been a Director of a number of industry bodies. He has been involved in task forces and advisory bodies to Government. Currently he is a Director of HPAL Limited, Avant Insurance Limited, Hannover Life Re and ING Foundation and is Chairman of Macquarie University Actuarial Foundation. Rodney’s extensive experience in actuarial management and financial administration led to his appointment to the Board of the CMRI in February 2001 and election as Treasurer in December 2001. Professor Ian Caterson AM MBBS BSc (Med) PhD FRACP Ian Caterson is Boden Professor of Human Nutrition and Head of the School of Molecular and Microbial Biosciences, University of Sydney. Previously, he was Senior Staff Specialist and Director of Clinical Endocrinology at Royal Prince Alfred Hospital. He was a post-doctoral researcher at the University of Oxford with Professor Sir Philip Randle FRS. His research interests have been in insulin resistance and the causes, prevention and treatment of obesity. He is a past President of the Australian Diabetes Society and the Australasian Society for the Study of Obesity. He is on the management committee of the International Obesity Task Force and a regional advisor on Obesity for the World Health Organisation. He is regional vice-president (AsiaOceania) for the International Association for the Study of Obesity. Currently he is Co-Chair of the 10th International Congress of Obesity. Ian joined the Board of the CMRI in 2004. John Bevins is an advertising copywriter and Creative Director of independent Australian advertising agency John Bevins Pty Limited. He has long been interested in advertising as a positive social force. His agency was established in 1982 on work that included NSW’s highly successful anti-smoking and Random Breath Testing campaigns, and it continues to create social marketing and brand campaigns for clients such as the Roads and Traffic Authority, Toshiba and Perpetual. Jeans for Genes was an initiative of the John Bevins agency, created in a brainstorm with scientists from the Institute. In 2001, John was awarded the inaugural Advertising Federation of Australia (AFA) medallion for his contribution to the advertising industry, primarily through his work as Chairman of the AFA Ethics Working Party. He has been a member of the CMRI Board since 1986. Mr Christopher Cullen AM ED BE FAIM Christopher Cullen has been a member of the CMRI and the Board of the Institute since incorporation and was President from 1985 to 1995. He was President of the State, the Australian and the International Chambers of Commerce successively from 1982 to 2001. From 1992 to 1998 he was Chairman of both Australian Hearing (the National Acoustic Laboratory) and the NSW Casino Control Authority. He was formerly the Honorary Treasurer of the Royal Blind Society and The Children’s Hospital at Westmead. He was the Chief Executive and a Director of the ACTA Group from 1985 to 1991. Mr John Dunlop AM John Dunlop was a member of the Management Committee of CMRI from 1973 to 1985, serving as President from 1983 to 1985. As an inaugural member of the Board of the Institute he served as Honorary Treasurer from 1985 until 1991. He is a Director of the Hospitals Contribution Fund of Australia Limited and Health Super Pty Ltd. He was President of The Children’s Hospital at Westmead from 1983 to 2007 and Managing Director of Edwards Dunlop and Company Limited between 1978 and 1989. The Hon Craig Knowles The Hon Craig Knowles holds a number of advisory roles and directorships in the health, finance, property, planning and aged care sectors. His roles include: President, Planning Research Centre, Sydney University; Member of the Advisory Committee, Urban Research Centre, University of Western Sydney; Director, Odyssey House; Director, Northern Medical Research Foundation; Chairman of Trustees, Casula Powerhouse Arts Centre Trust Fund; Advisor, Investec Bank (Australia) Ltd and Director, Tulich Family Communities Aged Care. Craig was a senior Minister in the New South Wales Government for 10 years, serving in the portfolios of Planning and Housing (1995-1999), Health (1999-2003), Infrastructure, Planning and Natural Resources (2003-2005) and Minister for Forests and Minister for Lands (2003-2005). He is a Fellow of the Australian Property Institute and a Certified Practicing Valuer. Craig joined the CMRI Board in May 2007. 2 2 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Directors Professor Andrew Kemp MBBS PhD FRACP Andrew Kemp is Professor of Paediatric Allergy in the Department of Allergy, Immunology and Infectious Diseases, The Children’s Hospital at Westmead. He was Staff Specialist in Clinical Immunology at Flinders Medical Centre, South Australia and Head of the Department of Immunology at the Royal Alexandra Hospital for Children, Camperdown, 1979-1989. In 1990 he was Director of Clinical Immunology, Director of Paediatric Physician Training and Head of the General Medical Unit at the Royal Children’s Hospital at Melbourne. He has held appointments as President of the Paediatric Research Society of Australia, a Councillor of the Australian College of Paediatrics, a Member of the Committee for Examinations of the Royal Australasian College of Physicians and Chairman of the Written Exam Committee in Paediatrics of the Royal Australasian College of Physicians. His research interests have included the epidemiological aspects of and immune responses in allergic disease in childhood. He is an editorial board member of the Journal of Pediatric Allergy and Immunology. He joined the Board of the CMRI in 2003. Ms Elizabeth Hallett LLB BCom Professor Kathryn North MD BSc (Med) FRACP Elizabeth Hallett is a partner in the national law firm, Deacons. Now based in Sydney, Elizabeth commenced her career in Melbourne in 1983, worked in Washington DC in 1989 and was managing partner of Deacons’ Jakarta office from 1992 until 1996. Elizabeth is the national leader of Deacons’ Corporate and Commercial Business Unit and her practice focusses on corporate matters including corporate governance issues and Corporations Act advice. Elizabeth is also a member of the Board of Directors of the Australia Indonesia Institute. Elizabeth was appointed to the Board of Directors of the Institute in 2001. Kathryn North is Head of the Neurogenetics Research Unit, Deputy Head of the Institute for Neuromuscular Research and Associate Dean of the Clinical School, The Children’s Hospital at Westmead. She is also the Douglas Burrows Professor and Head of the Discipline of Paediatrics and Child Health, Faculty of Medicine, University of Sydney. Following a Postdoctoral Fellowship in Boston she returned to Australia in 1995 as the recipient of the Children’s Hospital Research Career Development Award. Her research interests focus on inherited childhood muscle disorders and neurofibromatosis. In 2000 she received the Sunderland Award for achievement in neurobiological research. Kathryn is past Chairman of the Children’s Hospital Research Laboratories Committee and an Executive Board member of the World Muscle Society. She is currently a member of the Children’s Hospital Research Executive and Research Committee, and the University of Sydney Medical Faculty Advisory Committee. She is Chairman of the Human Genetics Society of Australasia Scientific Program Committee and the Genetics Sub-Committee of the Australian Association of Neurologists. She joined the Board of the CMRI in 2000. Mrs Patti Payne OAM MPS PhC Patti Payne has been a Community Pharmacist for over 25 years, practicing on the Central Coast, NSW. She joined the Beecroft Committee of the CMRI in 1969, serving as President in 1972/1973. In 1991 she was instrumental in forming the Hills Committee and has been its President ever since. She is a member of the CMRI Biosafety Committee and has been heavily involved with Jeans for Genes since its inception. She has served on the Board of Trustees of the Kings School Foundation and has organised many functions for other institutions and charities. She is the founding President of the Women for Pharmacy network, Chairperson of the Events and Hospitality Committee of the Federation Internationale Pharmaceutique (FIP) World Conference, Sydney, 2003 and is the Australian nominee to the Board of Directors of the Community Pharmacy Section of FIP. She has four adult children. A fifth died in infancy from a genetically related condition. She was awarded the Medal of the Order of Australia in 2006. Patti was elected to the Board in October 2000. Professor Graeme Stewart AM BSc (Med) MBBS PhD FRACP FRCPA Graeme Stewart was appointed as founding head of Immunology at Westmead Hospital in 1980. He is the inaugural Director of the Institute for Immunology and Allergy Research, one of the four founding research groups of the Westmead Millennium Institute. Graeme was the inaugural President of the Australasian Society for HIV Medicine and has played a role at a national and international level in HIV policy, medical education and research. He is a member of the Board of Multiple Sclerosis Research Australia, Chair of the Clancey Donald Foundation and on the governing council of the Global Health Institute. His research group focusses on the genetics of autoimmune disease, particularly multiple sclerosis, HIV and allergies. He is a past Chairman of the Westmead Medical Staff Council and is Co-Chair of the NSW Medical Staff Executive Council. He has also been Deputy Chair of the Greater Metropolitan Clinical Taskforce. He has served on the CMRI Board since 2002. Dr Roger Reddel BSc (Med) MBBS PhD FRACP, Acting Director CMRI Roger Reddel heads CMRI’s Cancer Research Unit and is a Senior Principal Research Fellow of the NHMRC and the Faculty of Medicine, University of Sydney. He obtained a medical degree from the University of Sydney and trained in medical oncology at the Royal Prince Alfred Hospital. Roger completed a PhD in cancer cell biology at the Ludwig Institute for Cancer Research, University of Sydney, and received an NHMRC CJ Martin Fellowship and a Fulbright Fellowship to undertake postdoctoral research at the National Cancer Institute, Bethesda, Maryland, USA. He returned to Sydney to establish a laboratory with the support of Cancer Council NSW’s Bicentennial Fellowship. Dr Reddel is an editorial board member of several cancer journals, and served a term as editor of Carcinogenesis. He serves on research advisory panels, including Cancer Council NSW’s Cancer Research Committee, and is a Director of Cure Cancer Australia Foundation (CCAF). – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 2 3 CMRI staff – A N D S T U D E N T S – Acting Director Kelly Morgan Assistant Jeans for Genes Campaign Manager (Maternity Leave) BioServices Staff Lynda Dave BSocSci (SW) Genie/ BioServices Manager Executive Assistant to the Director Volunteer Coordinator Jeans for Genes Bernadeth Gonzaga DVSM, Margaret La Rosa JP (part-time) Melissa Nassif Assistant Jeans for Technical Officer Acting Deputy Director Genes Campaign Manager (Maternity Leave cover) Carlie Crawford Animal Technician Roger Reddel BSc (Med) MBBS PhD FRACP Patrick PL Tam BSc (Hons) MPhil PhD EurProBiol CBiol FIBiol Jan Mullin FPNA MComm Manager, Administration and Community Relations and Company Secretary Administrative Officer and Accountant Deepa Desikan Assistant Accountant Stephen Ryall BHA FFIA MAUSAE AMAMI Valeria Souto Accounts Clerk (part-time) Administration and Appeals Staff Operations Kylie Ritson Personal Assistant to the Greg Craig MPhil (Arch), Grad Dip Fac Mgt, Grad Dip Opt Mgt Operations Manager Manager, Administration and Community Relations and Office Manager Denise Schelin, Administrative Assistant/ Karina Picton Animal Attendant Kerrie McDonald Animal Attendant Megan Reddel Animal Technician Mehtap Baserdem Animal Technician Melissa Jones Animal Technician Shelley Dimech Animal Technician Cancer Research Unit Unit Head Roger Reddel BSc (Med) MBBS PhD FRACP Akira Nguyen BMedSc (Hons) Daphne Wilken Laboratory Assistant Data Entry Operator (from May 2007) PhD Student Donna Cranshaw Personal Assistant Dianna Maltese Administrative Assistant Alessandra Muntoni MD MSc PhD to Operations Manager Doreen Molasky BSc (Hons) MSc Laboratory Manager (from Sept 2006) Postdoctoral Fellow Helena West Administration and Andy Chang BSc (Hons) PhD Community Relations Assistant Senior Research Officer Ella Rizzo Laboratory Assistant Jodie Mariner Administrative Assistant Antony Cesare BSc PhD Janet Moran Laboratory Assistant Julia Cognet Manager, Special Projects Mila Tittel BA (Hons) Dip Ed MAppLing Senior Technical Officer and Privacy Officer (part-time) Robert Denne Maintenance Officer Mary Donnelly Personal Assistant to Information and Communications Technology Director (part-time) Marjana Curkovic Receptionist Darryn Capes-Davis BE (Hons) Sandra Dillon Administrative Assistant/ Data Entry Operator Manager, Information and Communications Technology Vickie Micallef Administrative Assistant/ Data Entry Operator (part-time) (until May 2007) Alvin Sebastian BA BLaws, Dip Bus Programming Information Systems Officer Volunteer Assistants Postdoctoral Fellow Axel Neumann Dipl Biol Senior Research Officer, PhD Student Clare Fasching BSc MSc Judith Hyam Memorial Scholar, PhD Student (until March 2007) Elizabeth Collins BAppSc (Med Lab Sci) Scientific Administrator Hilda Pickett BSc PhD Promina Postdoctoral Research Fellow Jane Noble BAppSc (BioMed Sc) MSc (Med) Senior Research Officer Community Relations and Science Communication Bruce Clark, Denva Barber, Diana Mahony, Helen Pearce, Janet Cooper, Jennifer Trevarrow, Lesley Brooks, Linda Facaris, Maria Krikelis, Mark Pearce, Shirley and David Gibbs, Val Ryan (from July 2006) Jennifer Philps BSc (Hons) Dip Ed Mass Spectrometry Facility Jonathan Moore BioMedSci (Hons) Community Relations Officer Valentina Valova BSc (Hons) MAppSc Jane Fleming BSc (Hons) PhD Manager, Mass Spectrometry Facility Science Communication Officer CellBank Australia Lisa Melton BSc (Hons) PhD Science Communication Officer (part-time) Amanda Capes-Davis MBBS PhD Ruth Hardman BSc Adv, Grad Dip Sci Comm Science Communication Officer Elsa Moy BAppSc Research Assistant (part-time) Jeans for Genes George Theodosopoulos BSc Julijana Trifunovic Dip HSc, MFIA Research Officer National Campaign Manager, Jeans for Genes Monica Logan BBiomedSc Artur Gibalka CCNA ICT Assistant Bill Kotsifas Applications Officer Edward Zhang Security Officer 2 4 – C M R I Accounts Irma Villaflor DVM, MPVM Manager, CellBank Australia Research Officer (part-time) (part-time) Jennifer Plowman BSc Masters Student Jeremy Henson BSc (Hons-Biochem; Maths) MBBS PhD Postdoctoral Fellow Research Assistant (until Jan 2007) Kylie Bower BBiotech (Hons) Research Assistant, Masters Student (Feb 2006) Lily Huschtscha BSc (Hons) PhD Senior Research Officer Lorel Colgin BSc PhD Senior Research Officer Nancy Martin BSc MSc Research Assistant (from July 2006) Scott Cohen BSc PhD (Chemistry) Senior Research Officer (until March 2007) Christine McGee Dip PR MFIA Special Wei-Qin Jiang BSc MSc PhD Senior Events Manager Jeans for Genes Research Officer 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Ying Cao BSc (Med) MMedSc (Biochem) PhD Postdoctoral Fellow Michael Lee University of Sydney Summer Scholarship Student (Dec 2006-Jan 2007) Andrew White BMedSci (Hons) MBBS PhD Research Fellow (part-time) Ze Huai Zhong BSc (Hons) PhD Nicole Santucci BSc (Hons) Chris Willcock BSc (Hons) Research Student (until June 2007), Research Officer (from June 2007) Research Assistant Assistant (until Dec 2006) Nicole Vlahovich BSc (Hons) Gene Therapy Research Unit PhD Student (to March 2007), Research Officer (to Oct 2007) Luke St Heaps BSc (Hons) Masters Student (part-time) Unit Head Ian Alexander BMedSci MBBS (Hons) PhD FRACP (Paeds) HGSA Clinical Geneticist Marija Mihelec BSc (Hons) Prathibha Kahatapitiya BSc (Hons) PhD Student, Australian Postgraduate Award Scholar PhD Student Afroditi Spinoulas BMedSci (Hons) Renee Szokolai Honours Student Research Assistant (Maternity Leave) (March-Nov 2007) Aiman Jajo Honours student Stephen Palmer BSc (Hons) PhD (from Feb 2007) Senior Research Officer Allison Dane BSc (Hons) Embryology Unit Assistant (from Feb 2007) Research Assistant Unit Head Patrick Tam BSc (Hons) Yongjuan Chen BMed MMed PhD Christine Smyth MSc PhD Senior MPhil PhD EurProBiol CBiol FIBiol Research Assistant Abidali Mohamedali BSc (Hons) PhD Student, University of Sydney Endeavour International Postgraduate Research Scholar and International Postgraduate Award Scholar Sir Norman Gregg Postdoctoral Fellow (from Jan 2007) Cindy Kok BSc (Hons) PhD Student (from March 2007) Grant Logan BAppSc MSc Senior Research Assistant Peter Abraham BSc Honours student, Macquarie University Rebecca Storen BMed Sci University of Sydney/Save Sight Institute Research Cell Signalling Unit Unit Head Phillip Robinson BSc (Hons) PhD Andrew McGeachie BSc (Hons) PhD PhD Student David Loebel BSc (Hons) PhD Kimberly-Clark Research Fellow Julie Curtin MBBS (Hons) FRACP FRCPA PhD Clinical Researcher Germaine Trusi, University of Applied Sciences, Mannheim, Germany, Research Assistant (from Feb 2007) Visiting Student (Mar-Aug 2007) Research Assistant (until Feb 2007) Jerome Laurence MBChB MRCS Maolin Zheng MSc (Vet) MSc Senior Research Assistant Margot Latham BSc Research Administrator Samantha Ginn BSc (Hons) PhD Noel Dowling Research Fellow Sharon Cunningham BSc (Hons) PhD Research Officer Muscle Development Unit Unit Head Edna Hardeman BSc BA (Hons) PhD Postdoctoral Fellow (since July 2006) Christine Lucas BSc (Hons) PhD Research Officer (from Feb 2007) Chandra Malladi BSc BEd MSc PhD Research Officer Charlotte Smith BSc (Hons) Research Assistant (from March 2007) Jane Seaman Personal Assistant to Ellen van Dam MSc PhD Research the Head Officer (until Aug 2006) Joshua Studdert BSc (Hons) George Craft BSc (Hons) PhD Student Research Assistant Kirsten Steiner BSc (Hons) MSc Antonio Lee BSc (Hons) PhD Visiting Research Assistant Research Assistant (to Nov 2006) Gurdip Hansra BSc (Hons) Research Assistant Jane Seaman Personal Assistant to the Head Jing Xue BSc MSc PhD Senior Research Senior Research Officer Officer (until Sep 2006) Melinda Power BSc (Hons) Lingshan Chan BBiomedSc (Hons) Senior Technical Officer Research Assistant (from Jan 2007) Poh-Lynn Khoo BSc (Hons) Lin Luo BSc (Hons) PhD Student Senior Technical Officer Elie Matar University of Sydney Summer Scholarship Student (Dec 2006-Feb 2007) Renuka Rao BSc PhD Research Officer (until Aug 2006) Emma Kettle BSc MSc Research Assistant Sabine Pfister BSc PhD Deutscher Akademischer Austauschdienst Fellow Enoch Tay BSc (Hons) PhD Samara Lewis BSc (Hons) PhD Research Officer Jessica Webster Summer Work Experience Student (Dec 2006 – Jan 2007) Jocelyn Widagdo Honours Student (to Nov 2006) PhD Student (from Feb 2007) Josephine Joya DVM Research Officer Kata Popovic Assoc Degree Med Sci Research Assistant Mai-Anh Nguyen BSc (Hons) Postdoctoral Fellow Megan Fabbro BSc (Hons) PhD Peter Doherty Fellow Nancy Sue BMedSc (Hons) PhD Senior Technical Officer Research Officer (from March 2007) Vanessa Franklin BSc (Hons) Ngoc Chau BChemEng (Hons) MBiomedEng Research Assistant Research Assistant Yvette Jackson BSc Honours Student, Macquarie University Sanket Joshi BSc (Biotech) MBiotech PhD Student (joint with Cell Eye Genetics Group, Embryology Unit Merritt Adams BA PreMed Work Clinical Geneticist Maggie Ma BSc Bioinfo (Hons) Mark Graham BSc (Hons) PhD Tania Radziewic Biol Tech Cert Group Leader Robyn Jamieson, MBBS PhD FRACP, HGSA BMedSci (from March 2007) Research Assistant (from Feb 2007) Research Officer (until March 2007) PhD Student Anna Powell BSc (Hons) Annie Quan BSc (Hons) MComm Heidi Bildsoe BSc MSc Anthony Kee BSc (Hons) PhD Senior Research Officer Anna Mariana BBiotech Adv (Hons) Gregory Pelka BBiomedSci (Hons) PhD Rett Foundation Post-doctoral Fellow and NHMRC Peter Doherty Australian Biomedical Fellow Kenneth Soo BSc (Hons) MBBS PhD Student, University of Sydney Medical Foundation Scholar Agnes Chan Honours Student Research Officer Transformation Unit) (from March 2007) Valentina Valova BSc (Hons) MAppSc Senior Research Officer, Mass Spectrometry Facility Manager Experience Student (Jan-Feb 2007) – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 2 5 Office Bearers Victor Anggono BSc (Hons) PhD Student Patron Cell Biology Unit Unit Head Tracy Bryan BSc (Hons) PhD Amanda Nouwens BSc (Hons) PhD NHMRC Peter Doherty Postdoctoral Fellow (to March 2007) Julie Jurczyluk BSc (Hons) Her Excellency Professor Marie Bashir AC, Governor of New South Wales Acting Director Roger Reddel BSc (Med) MBBS PhD FRACP Research Assistant Board of Directors Liana Oganesian BMedSc (Hons) Andrew Kemp MBBS PhD FRACP PhD Student (NHMRC Biomedical Postgraduate Scholarship) Carolyn Forster OAM, Vice President Christopher Cullen AM ED BE FAIM Sharon Finger BSc (Hons) Research Assistant (to March 2007) The Hon Craig Knowles Cell Transformation Unit Elizabeth Hallett LLB BCom Unit Head Antony Braithwaite BSc Frank Martin MBBS FRANZCO FRACS AM Oph, President MSc (Hons) PhD Research Assistant Graeme Stewart AM BSc (Med) MBBS PhD FRACP FRCPA Daniel Speidel Dr. rer. nat. DiplBiochemiker Postdoctoral Fellow Ian Caterson AM MBBS BSc (Med) PhD FRACP (from June 2007) John Bevins Hamish Campbell BSc (Hons) PhD (pending) Postdoctoral Fellow (from John Dunlop AM Carina Rubio BSc (Hons) Kathryn North MD BSc (Med) FRACP March 2007) Rodney Atfield FIA FIAA FAII, Treasurer Priya Ganesan BSc (Hons) PhD Roger Reddel BSc (Med) MBBS PhD FRACP Acting Director Postdoctoral Fellow Reena Mehta BSc MSc PhD CMRI/CHW Animal Care and Ethics Committee (ACEC) Co-Chairs Ian Alexander BMedSci MBBS (Hons) PhD FRACPC (Paeds) CG HGSA Head Gene Therapy Research Unit, CMRI Patrick Tam BSc (Hons) MPhil PhD EuroProBiol CBiol FIBiol Head Embryology Unit, CMRI Category A (Veterinarian) Irma Villaflor DVM MPVM, BioServices Manager, CMRI Tanya Stephens BVSc, Honorary Consulting Veterinarian Category B (Animal Researcher) Andy Chang BSc (Hons) PhD Senior Research Officer, Cancer Research Unit, CMRI Samantha Ginn BSc (Hons), PhD Research Officer, Gene Therapy Research Unit, CMRI Tanya Butler PhD Pathology, Postdoctoral Scientist, Institute for Neuromuscular Research, CHW Thomas Fath PhD Biology, Research Officer, Oncology Research Unit, CHW Category C (Animal Welfare) Patti Payne OAM MPS PhC Barry Philps BVMSc MRCVS WIRES Secretary to the Board of Directors Stephen Ryall BHA FFIA MAUSAE AMAMI David Edwards MA FIA FIAA WIRES Audit and Risk Committee Category D (Layperson) Senior Research Officer (from March 2007) Christopher Cullen AM ED BE FAIM Denva Barber Weina Ma BSc (Hons) Carolyn Forster OAM Research Assistant Elizabeth Hallett LLB BCom CMRI Research Associates Luciano Dalla-Pozza MBBS FRACP Frank Martin MBBS FRANZCO FRACS AM Oph Margaret Tipper BBus (UWS) GD Comm Mgt (UTS) AHRI AIMM St Vincent de Paul Executive Observer The Children’s Hospital at Westmead The Children’s Hospital at Westmead John Bevins Peter Gunning BSc (Hons) PhD Rodney Atfield FIA FIAA FAII Chairman Karen Brennan MSc Manager, Transgenic Facility CHW Investment and Finance Committee Secretary/Contact Officer Carolyn Forster OAM Jane Seaman, CMRI Christopher Cullen AM ED BE FAIM Administrative Assistant Elizabeth Hallett LLB BCom Donna Cranshaw, CMRI Research Assistant Sanket Joshi BSc (Hons) PhD Student (joint with Cell Signalling Unit) } This is not a journey for the faint-h Scott Cohen BSc PhD (Chemistry) The Children’s Hospital at Westmead Renu Wadhwa PhD National Institute of Advanced Industrial Science and Technology (AIST) Japan Sunil Kaul PhD National Institute of Advanced Industrial Science and Technology (AIST) Japan Frank Martin MBBS FRANZCO FRACS AM Oph Honorary Consulting Veterinarian Jan Mullin FPNA MComm Tanya Stephens BVSc John Bevins Institutional Biosafety Committee Chairman Rodney Atfield FIA FIAA FAII Chairman Roger Reddel BBSc (Med) MBBS PhD FRACP Roger Reddel BSc (Med) MBBS PhD FRACP Secretary Stephen Ryall BHA FFIA MAUSAE AMAMI Jennifer Byrne BSc (Hons) PhD Carolyn Casey LBB (Minutes Secretary) Layperson Patti Payne OAM MPS PhC 2 6 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Scholarships Committee Biomedical Engineer and Biological Safety Jane Noble BAppSc (BioMed Sc) MSc (Med) Darren McKinnon B Eng (Mech) Jennifer Philps BSc (Hons) Dip Ed Greg Craig MPhil (Arch) Grad Dip Fac Mgt, Grad Dip Opt Mgt Julie Jurczyluk BSc (Hons) (from May 2007) Leanne Mills BSc (Hons) PhD Julijana Trifunovic Dip HSc MFIA Microbiology Kirsten Steiner BSc (Hons) MSc (from 2007) Jeans for Genes Executive Committee Lynda Dave BSocSci (SW) (from 2007) Andrew Cummings, Clorox Australia, New Zealand and Africa Elizabeth Deane BSc PhD (External member) Molecular Biology/Genetics Mai Anh Nguyen BSc (Hons) Alison Kesson MBBS PhD FRACP FRCPA Melissa Jones (animal attendant) John Christodoulou MBBS PhD FRACP FRCPA Occupational Health and Safety Committee Antony Braithwaite BSc MSc (Hons) PhD Phillip Robinson Bsc (Hons) PhD Tracy Bryan Bsc (Hons) PhD, Chairman Andrew Glad, Andrew Glad and Associates Ruth Hardman BSc Grad Dip Sci Comm, Chairman Andrew McKenzie, Impulse Purchase Specialists Weini Ma BSc (Hons) Anita Batho, Torch Grants Advisory Committee Brian Moran, Managing Values Charlie Brown, The Discovery Group Donna Cranshaw Antony Braithwaite BSc MSc (Hons) PhD Doreen Molasky BSc (Hons) MSc Antony Kee BSc (Hons) PhD Enoch Tay BSc (Hons) PhD David Loebel BSc (Hons) PhD Grant Logan BAppSc MSc Julijana Trifunovic Dip HSc MFIA Greg Craig MPhil (Arch) Grad Dip Fac Mgt, Grad Dip Opt Mgt Lisa Melton BSc (Hons) PhD, Secretary Gary Williams, Perfection Badges Irma Villaflor DVM MPVM Lorel Colgin BSc PhD John Glover, Pendragon Jane Noble BAppSc (Biomed Sc) MSc Megan Fabbro BSc (Hons) PhD Julie Jurzcyluk BSc (Hons) Stephen Ryall BHA FFIA MAUSAE AMAMI John Coughlin, John Bevins Pty Limited Daphne Wilken Kirsten Steiner BSc (Hons) MSc Chairman Liz Collins BAppSc (Med Lab Sc) Christine Gabiola, PricewaterhouseCoopers Australia Felicity Hyde, Feehan Communications Jennifer Philps, CMRI Julijana Trifunovic, Jeans for Genes Phillip Robinson BSc (Hons) PhD, Chairman Kelly Morgan, Jeans for Genes Leah Daly, Cherry Media { hearted. It is an ongoing challenge. Monica Logan BBiomed Sci Nancy Sue BMedSc (Hons) PhD Weini Ma BSc (Hons) Intellectual Property Committee Frank Martin MBBS FRANZCO FRACS AM Oph, Chairman Roger Reddel BSc (Med) MBBS PhD FRACP Acting Director, CMRI Stephen Ryall BHA FFIA MAUSAE AMAMI Member with legal qualifications nominated by the Board Elected member of the CMRI Senior Scientific Staff Internal Communications Committee Afroditi Spinoulas BMedSci (Hons) Amanda Nouwens BSc (Hons) PhD Andrew McGeachie BSc (Hons) PhD Darryn Capes-Davis BE (Hons) Jane Fleming BSc (Hons) PhD Mary Cotter, Walkley Foundation Bioservices Management Committee Megan Mair, MOKEM Agency/ Design Lab Andy Chang BSc (Hons) PhD (Group Representative) Morag Burke, Board of Directors Darryn Capes-Davis BE (Hons) (Ex Officio Member) Nigel Turner, Outsource Marketing Services Donna Cranshaw (Minutes Secretary) Norelle Feehan, Feehan Communications Edna Hardeman BSc BA (Hons) PhD (Group Representative) Ray Simmons, John Bevins Pty Limited Greg Craig MPhil (Arch) Grad Dip Fac Mgt, Grad Dip Opt Mgt (Chair of Committee) Sally Anne Trigg, Kimberly Clark Australia Pty Ltd Gregory Pelka BSc (Hons) PhD (Group Representative) Sue Stanbridge, Hotsource.com.au Pty Ltd Irma Villaflor DVM MPVM (Ex Officio Member) Auditor Stephen Ryall, CMRI HLB Mann Judd Mark Graham BSc (Hons) PhD (Group Representative) Solicitors Patrick Tam BSc (Hons) MPhil PhD EurProBiol CBiol FIBiol (Ex Officio Member) Allens Arthur Robinson (Pro Bono) Dibbs Abbott Stillman Priya Ganesan BSc (Hons) PhD (Group Representative) Minter Ellison Sharon Cunningham BSc (Hons) PhD (Group Representative) – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 2 7 Leading international thinking – P U B L I C A T I O N S – PROUDLY CASTING IDEAS TO THE WORLD Continuous output DRIVING RESEARCH AND DEVELOPMENT COMPETING ON AN international scale. Anggono V, Cousin MA & Robinson PJ. Styryl dye-based synaptic vesicle recycling assay in cultured cerebellar granule neurons. In Membrane Trafficking, Humana Press. (Book chapter.) In press. Anggono V & Robinson PJ. Key Molecules: Dynamin. In Encyclopedia of Neuroscience, 4th Edn, Elsevier. (Book chapter.) In press. Anggono V & Robinson PJ. Syndapin I and endophilin I bind to overlapping proline-rich regions of dynamin I: Role in synaptic vesicle endocytosis. J. Neurochem. 102, 931-943, 2007. Anggono V, Smillie KJ, Graham ME, Valova VA, Cousin MA & Robinson. PJ Syndapin I is the phosphorylation-regulated dynamin I partner in synaptic vesicle endocytosis. Nat. Neurosci. 9, 752-760, 2006. Bryan TM & Jarstfer MB. Interrogation of G-quadruplexprotein interactions. Methods. In press, 2007. Butler TL, Au CG, Yang B, Egan JR, Tan YM, Hardeman EC, North KN, Verkman AS & Winlaw DS. Cardiac aquaporin expression in humans, rats, and mice. Am J Physiol Heart Circ Physiol. 2006 Aug; 291(2): H705-13. Epub 31 Mar 2006. Cesare AJ & Reddel RR. Alternative lengthening of telomeres in mammalian cells. In: Nosek J and Tomáska L (eds) Origin and Evolution of Telomeres, In press, Landes Biosciences, 2007. Chen W, Ruell PA, Ghoddusi M, Kee A, Hardeman EC, Hoffman KM & Thompson MW. Ultrastructural changes and SR Ca2+ regulation in red vastus muscle following eccentric exercise in the rat. Exp Physiol. 92: 437-47, 2007. 2 8 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Chen Y-J, Hakin-Smith V, Teo M, Xinarianos GE, Jelinek DA, Carroll T, McDowell D, MacFarlane MR, Boet R, Baguley B, Braithwaite AW, Reddel RR & Royd JA. Association of mutant TP53 with ALT and favorable prognosis in glioma. Cancer Res. 66: 6473-6476 2006. Fu Dvan Dam EM, Brymora A, Duggin IG, Robinson PJ & Roufogalis BD. The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein. Biochimica et Biophysica Acta – Molecular Cell Research. doi:10.1016/j.bbamcr.2007.03.023, 2007. Clarke NF, Ilkovski B, Cooper S, Valova VA, Robinson PJ, Nonaka I, Feng JJ, Marston S & North KN. The pathogenesis of ACTA1-related congenital fibre type disproportion. Ann. Neurol. 61, 552-561, 2007. Ganesan PL, Alexander SL, Watson D, Logan GL, Zhang DY & Alexander IE. Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression. Cancer Immunol Immunother. Jun 5; [Epub ahead of print], 2007. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ & Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science 315(5820), 1850-1853, 2007. Cooper ST, Kizana E, Yates JD, Lo HP, Yang N, Wu ZH, Alexander IE & North KN. Dystrophinopathy carrier determination and detection of protein deficiency in muscular dystrophy using lentiviral MyoD-forced myogenesis. Neuromuscular Disorders. 17(4):276-284, 2007. Costa A, Daidone MG, Daprai L, Villa R, Cantù S, Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel RR & Zaffaroni N. Expression and clinical relevance of telomere maintenance mechanisms in liposarcoma. Cancer Res. 66: 8918-24, 2006. Crock PA, Bensing S, Smith CJ, Burns C & Robinson PJ. Pituitary autoantibodies. Curr Opin Endocrinol Diabetes, 13, 344-350, 2006. Crock PA, Burns C, Bensing S, Smith C & Robinson PJ. Autoimmune Hypophysitis. In Autoimmune Diseases in Endocrinology (Book chapter) (Weetman, AP, ed.), Humana Press. In press. Domazetovska A, Ilkovski B, Cooper ST, Ghoddusi M, Hardeman EC, Minamide LS, Gunning PW, Bamburg JR & North KN. Mechanisms underlying intranuclear rod formation. Brain 2007. Accepted. Domazetovska A, Ilkovski B, Kumar B, Valova VA, Vandebrouck A, Hutchinson DO, Robinson PJ, Cooper ST, Sparrow JC, Peckham M & North KN. Intranuclear rod myopathy: molecular pathogenesis and mechanisms of weakness. Ann. Neurol (Epub Aug 2007). Fasching CL, Neumann AA, Muntoni A, Yeager TR & Reddel RR. DNA damage induces ALT-associated PML Bodies that preferentially associate with linear telomeric DNA, Cancer Res., In press, June 12, 2007. Franklin VJ, Bildsoe H & Tam PPL. Fate-mapping technique: Grafting fluorescent cells into gastrula-stage mouse embryos at 7-7.5 days post coitum. Cold Spring Harbor Protocol (In press). } Graham ME, Anggono V, Bache N, Larsen MR, Craft GE & Robinson PJ. The in vivo phosphorylation sites of rat brain dynamin I. J. Biol. Chem. 10.1074/jbc. M609713200, 2007. Graham ME, Kilby DM, Firth SM, Robinson PJ & Baxter RC. The in vivo phosphorylation and glycosylation of human insulin-like growth factor binding protein-5. Mol Cell Proteomics (2007). Gunning PW, O’Neill G, Hardeman EC. Tropomyosinbased regulation of the actin cytoskeleton in time and space. Physiological Reviews 2007. Accepted. Hilliard LM, Osicka TM, Robinson PJ, Nikolic-Paterson DJ & Comper WD. Characterisation of the urinary degradation pathway in the isolated perfused rat kidney. J Lab Clin Med 137, 36-44, 2006. Jamieson R, Farrar N, Stewart K, Perveen R, Mihelic M, Carette M, Grigg J, McAvoy JW, Lovicu FJ, Tam PPL, Scambler P, Lloyd IC, Donnai D & Black GC. Characterisation of a familial t(16;22) balanced translocation associated with congenital cataract leads to identification of a novel gene, TMEM114, expressed in the lens and disrupted by the translocation. Human Mutation (In press). Jiang W-Q, Zhong Z-H, Henson JD & Reddel RR. Identification of candidate Alternative Lengthening of Telomeres (ALT) genes by methionine restriction and RNA interference. Oncogene, Published on-line, Feb 5, 2007. Khoo P-L, Franklin VJ, Tam PPL Fate-mapping technique: Targeted whole embryo electroporation of DNA constructs into the germ layers of 7-7.5 dpc mouse embryos. Cold Spring Harbor Protocol (In press). Kizana E, Chang CY, Cingolani E, Ramirez-Correa GA, Sekar RB, Abraham MR, Ginn SL, Tung L, Alexander IE & Marban E. Gene Transfer of Connexin43 Mutants Attenuates Coupling in Cardiomyocytes: Novel Basis for Modulation of Cardiac Conduction by Gene Therapy. Circulation Research. 100(11):1597-1604, 2007. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 2 9 { Kizana E, Ginn SL, Smyth C, Boyd A, Thomas SP, Allen DG, Ross DL & Alexander IE. Fibroblasts modulate cardiomyocyte excitability: Implications for Cardiac Gene Therapy. Gene Therapy. 13(22):1611-1615, 2006. Kozlov SV, Graham ME, Peng C, Chen P, Robinson PJ & Lavin MF. Involvement of novel autophosphorylation sites in ATM activation. EMBO J. 25, 3504-3514, 2006. Kramer BA, Lemckert FA, Alexander IE, Gunning PW & McCowage GB. Characterisation of a P140K mutant O6-Methyl-Guanine-Methyl-Transferase (MGMT) expressing transgenic mouse line with drug selectable bone marrow. Journal of Gene Medicine. 8(9):10711085, 2006. Lewis SL & Tam PPL. The definitive endoderm of the mouse embryo: Formation, cell fates and morphogenetic function. Developmental Dynamics 235:2315–2329, 2006. Lewis SL, Khoo P-L, De Young A, Bildsoe H, Wakamiya M, Behringer RR, Mukhopadhyay M, Westphal H & Tam PPL. Genetic interaction of Gsc and Dkk1 in head morphogenesis of the mouse. Mechanisms of Development 124, 157-165, 2006. Logan GJ, Wang L, Zheng M, Cunningham SC, Coppel RL & Alexander IE. AAV vectors encoding malarial antigens stimulate transgene-specific immunity but do not protect from parasite infection. Vaccine. 25(6):1014-1022, 2007. Neumann AA & Reddel RR. Telomerase independent maintenance of mammalian telomeres. In: T de Lange, V Lundblad and E Blackburn (eds) Telomeres and Telomerase. pp. 163-198, Second edition. Cold Spring Harbor Laboratory Press, 2006. Odell LR, Quan A, Chau N, Abagyan R, Robinson PJ & McCluskey A. Virtual screening and validation of a human dynamin I GTPase domain homology model. ChemMedChem, 2007. Oganesian L & Bryan TM. Physiological relevance of telomeric G-quadruplex formation: a potential drug target. BioEssays, 29, 155-165, 2007. Oganesian L, Graham ME, Robinson PJ & Bryan TM. Telomerase recognises G-quadruplex and linear DNA as distinct substrates. Biochemistry, In press, 2007. O’Leary MJ, Xue A, Scarlett CJ, Sevette A, Kee AJ & Smith RC. Parenteral versus enteral nutrition – effect on serum cytokines and the hepatic expression of mRNA of suppressor of cytokine signalling proteins, IGF-I and the growth hormone receptor in rodent sepsis. Crit Care. 11: R79, 2007 [Epub ahead of print]. 3 0 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Palmer SJ, Tay ESE, Santucci N, Bach TTC, Hook J, Lemckert FA, Jamieson RV, Gunning PW & Hardeman EC. Expression of Gtf2ird1, the Williams syndromeassociated gene, during mouse development. Gene Expr Patterns. 2007 Feb;7(4):396-404. Epub 1 Dec 2006. Pfister S, Steiner KA & Tam PPL. Gene expression pattern and progression of embryogenesis in the immediate post-implantation period of mouse development. Gene Expression Patterns 7(5): 558-573, 2007. Quan A, McGeachie AB, Keating DJ, van Dam EM, Rusak J, Chau N, Malladi CS, Chen C, McCluskey A, Cousin MA & Robinson PJ. MiTMAB is a surface-active dynamin inhibitor that blocks endocytosis mediated by dynamin I or dynamin II. Mol. Pharmacol. DOI: 10.1124/mol.107.034207, 2007. Quinlan GA, Khoo P-L, Wong N, Trainor PA & Tam PPL. Cell grafting and labelling in postimplantation mouse embryos. In: Molecular Embryology: Methods and Protocols (2nd edition). Methods in Molecular Biology Series (ISBN 9781 5882 94319), Edited by Paul Sharpe and Ivan Mason, Humana Press Inc., Totowa NJ (In press). Reddel RR. A SUMO ligase for ALT [News and Views]. Nature Struct. Mol. Biol., 14: 570-571, 2007. Robinson PJ. How to fill a synapse. Science 316, 551-553, 2007. (Perspectives.) Sanoudou D, Corbett MA, Han M, Ghoddusi M, Nguyen MA, Vlahovich N, Hardeman EC* & Beggs AH*. Skeletal muscle repair in a mouse model of nemaline myopathy. Hum Mol Genet. 2006 Sep 1;15(17):260312. Epub 28 Jul 2006. *These laboratories contributed equally to this study. Scarr E, Gray L, Keriakous D, Robinson PJ & Dean B. Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder. Bipolar Disord 8, 133-43, 2006. Shipman KL, Robinson PJ, King BR, Smith R & Nicholson RC. Identification of a family of DNA-binding proteins with homology to RNA splicing factors. Biochem. Cell Biol. 84, 9-19, 2006. Smyth CM, Ginn SL, Deakin CT, Logan GJ & Alexander IE. Limiting γc expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood. 110(1):91-98, 2007. Tam PPL, Khoo P-L, Lewis SL, Bildsoe H, Wong N, Tsang TE, Gad JM & Robb L. Sequential allocation and global pattern of movement of the definitive endoderm in the mouse embryo during gastrulation. Development 134, 251-260 (Accompanied by a Journal cover picture), 2007. Tam PPL, Loebel DAF & Tanaka SS. Mouse gastrulation: Signalling activities for lineage specification and embryonic patterning Current Opinion in Genetics and Development 16: 419-425, 2006. Tam PPL & Loebel DAF. Gene function in mouse embryogenesis: Get set for gastrulation. Nature Review Genetics 8: 368-381, 2007. Tan TC & Robinson PJ. Mechanisms of calcineurin inhibitor-induced neurotoxicity. Transplant Rev (Orlando) 20, 49-60, 2006. Tarran SL, Thomas G, Markham R, Craft GE, Valova VA, Robinson PJ, Langlois NE & Vanezis P. The use of proteomics to study wound healing: a preliminary study for forensic estimation of wound age. Med.Sci.Law 2007 Apr;47(2):134-40, 2007. van Dam EM & Robinson PJ. Ral: Mediator of membrane trafficking. Int. J. Biochem. Cell Biol. 38, 1841-1847, 2006. Wadhwa R, Takano S, Kaur K, Deocaris CC, PereiraSmith OM, Reddel RR & Kaul SC. Up-regulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int. J. Cancer 118: 2973-80, 2006. Watson CM, Trainor PA, Radziewic T, Pelka G, Zhou SX, Parameswaran M, Quinlan GA, Gordon M, Sturm K & Tam PPL. Application of lacZ transgenic mice to cell lineage studies In: Molecular Embryology: Methods and Protocols. Methods in Molecular Biology Series (ISBN 9781 5882 94319). Edited by Paul Sharpe and Ivan Mason, Humana Press Inc., Totowa NJ (In press). Yu Z-Y, McKay K, van Asperen P, Zheng M, Fleming J, Ginn SL, Kizana E, Latham M, Feneley MP, Kirkland PD, Lumbers ER & Alexander IE. Lentivirus vector-mediated gene transfer to the developing bronchiolar airway epithelium in the fetal lamb. Journal of Gene Medicine. 9(6):429-439, 2007. Zhang J, Lawrance GA, Chau N, Robinson PJ & McCluskey A. From Spanish fly to room temperature ionic liquids (RTILs): Synthesis, thermal stability and inhibition of dynamin 1 GTPase by a novel class of RTILs. New Journal of Chemistry. DOI: 10.1039/6707092f 2007. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 3 1 } Our global connections The scientists at the Children’s Medical Research Institute are not working alone. Worldwide, many medical researchers are working on closely related problems, each one contributing small pieces of the puzzle. CMRI scientists have established many alliances with colleagues throughout Australia and the world, frequently working across disciplines, to share expertise and research tools. The result of this global flow of ideas is a more rapid and accurate trajectory towards a common goal – establishing the foundation of knowledge that will transform our ability to more effectively treat and prevent disease. 3 2 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Seattle, Washington, USA Bethesda, Maryland, USA Berkeley, California, USA } Boston, Massachusetts, USA Toronto, Canada Fort Collins, Colorado, USA Americas San Diego, USA Chapel Hill, North Carolina, USA London, Ontario, Canada Houston, Texas, USA Hong Kong, China Baltimore, USA Sydney, Australia Seattle, Washington USA Brisbane, Australia Iowa City, Iowa, USA Melbourne, Australia Yale, USA Canberra, Australia Los Angeles, California, USA Newcastle, Australia Australasia/Asia Perth, Australia { Tsukuba, Japan Tokyo, Japan Dunedin, New Zealand Auckland, New Zealand Paris, France Milan, Italy Lincz, Austria Hamburg, Germany Cambridge, UK Athens, Greece Leicester, UK Edinburgh, UK { Munich, Germany Europe London, UK Odense, Denmark Helsinki, Finland – C M R I Heidelberg, Germany 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 3 3 The endless endeavour – C O M M U N I T Y R E L A T I O N S & F U N D R A I S I N G – SINCE OUR INCEPTION OUR FOUNDATION HAS BEEN FIRMLY BUILT UPON THE Community relations The Community Relations and Science Communication Group raises awareness and understanding of the research carried out at CMRI, supports the fundraising activities of the Institute and contributes to scientific literacy in schools and the community. Over the year we spoke at 166 schools and community groups and held twelve Discovery Days in which community members learned about genetics, listened to guest speakers and toured the facility. Over 100 science teachers attended our biannual Science Teachers Forum, where we provide a professional development program to complement the HSC Biology syllabus. CMRI scientists also contribute to these events, with tours, demonstrations and lectures. The team represented CMRI at various science exhibitions including Science in the City at the Australian Museum, Science EXPOsed at Hyde Park Barracks and the Amazing World of Science in Canberra. In collaboration with the Australian Museum we also hosted a successful Science in the Suburbs event with 57 school students visiting the Institute and a public seminar in the evening attended by 51 people. goodwill OF THE COMMUNITY. Kimberly-Clark Australia has generously sponsored our new Discovery Day booklets and a careers booklet for schools entitled It’s a Scientist’s Life. The inaugural in-house Science through the Lens science photography competition was a highlight, generating some beautiful scientific artwork to be displayed in the Institute and at Expos. Thank you to Canon, Big Colour, Fronine and Inside Out Restaurant for their sponsorship. Thanks also to Back to the Future Education who sponsored a series of four stunning postcards featuring scientific photographs by CMRI scientists. The redesigned CMRI website was launched this year making it a highly useable and current resource for community members and scientists. Our newsletter Under the Microscope also continues to provide a wealth of information to keep over 55,000 supporters per quarter informed of progress and events. A new focus this year has been the formation of the CMRI Grants Advisory Committee. Science Communication staff are contributing to this through the identification of philanthropic Trusts and Foundations whose goals match those of CMRI scientists. This will provide a targeted approach to generate much needed funds. 3 4 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Financial management The surplus available funds this year ($9.93 million), as has been the custom since our inception, were applied to the investment trust. This maintains and increases available income for research in the future, as well as providing additional funds which will need to be drawn as the CMRI plans its much needed expansion of research space and research activities in the near future. Net assets now stand at over $107 million of which over $94million is represented by the investment trust. Revenue from the trust this year represented over 42% of funds available for research. The balance of research funds came from successful grant applications at $6.18 million for the year. Our many supporters Since our inception in 1958 the CMRI’s foundations have been firmly built upon the goodwill and support of the community. It has been the driving force which has seen the CMRI emerge as one of the leading, independent research institutions in this country. We particularly acknowledge here our core group of volunteers who help out in the office each week enabling us to keep our administrative costs to a minimum. We thank Kimberly-Clark Australia and The Promina Group who each continue to support a named Research Fellowship. KimberlyClark Australia has also supported several of the outreach activities of the Science Communication Group and Jeans for Genes. We also thank Mrs Aileen Dowling for the Noel Dowling Memorial Fellowship and the Judith Hyam Memorial Trust Fund for Cancer Research whose generosity has enabled the continuance of two named research positions and the continued support of Drive for Charity M4, M5 and Eastern Distributor. Financial supporters of $1,000 or more and many who have donated services or goods in kind in the last financial year are listed later in this report. Unfortunately, due to space limitations, not all our generous supporters can be listed. Jeans for Genes Now in its thirteenth year Jeans for Genes® continues to raise significant funds for the CMRI with $4.02 million raised in 2006. We thank the millions of people who wore their jeans on Jeans for Genes Day 4 August 2006. The Jeans for Genes Art Auction was held at the Sofitel Wentworth Hotel, Sydney on 21 July 2006. Sixteen personally signed jeans from international celebrities were painted by Australian artists and auctioned. Hugh Jackman’s jeans painted by Nafisa Naomi sold for a record breaking $30,000 to John Symond of Aussie Home Loans. Major sponsors included Vietnam Airlines and The Leading Hotels of the World. Jamm for Genes®, a new initiative of Jeans for Genes, was a great hit, with over 100 venues and bands holding fundraising concerts throughout Australia. The Do it with Denim® Design Awards, now in its 2nd year, attracted over 300 entries from young design students designing garments from old jeans. In December 2006, the CMRI Board agreed to expand the Jeans for Genes team. New staff include Christine McGee – Special Events Manager, Lynda Dave – Genie (Volunteer) Coordinator, and Melissa Nassif who replaces Kelly Morgan as Jeans for Genes Campaign Assistant while she is on maternity leave. In May 2007, two new Jeans for Genes events were held including the Jeans for Genes Mothers’ Day lunch, organised by the CMRI Hills Committee with special guest, celebrity chef Kylie Kwong at The Hilton, Sydney. The inaugural Jeans on the Greens Golf Day was held at Oatlands Golf Course with corporate supporters and CMRI suppliers raising over $12,000. We plan to further expand Jeans for Genes beyond ‘the day’ and raise funds through new initiatives over the next three years. Once again we would like to thank our thousands of ‘Genies’ and other loyal supporters, including the retailers and jeans artists, for their generosity throughout the year. They are acknowledged elsewhere in this report. Fundraising Gross fundraising results this year amounted to $11.1 million – a record amount due primarily to a significant increase in funds received in bequests: over $4.8 million this year. The CMRI continues to be encouraged by the number of generous benefactors who provide for the CMRI in their wills, all of whom are convinced of the importance of basic research to secure the health of future generations. For many this conviction has come through the tragedy of personal experience. Two large bequests received from Florence Millar and Allan Hayward via our Gerringong and Northern Beaches Committees respectively, highlighted the importance of our committee network as ambassadors for CMRI in their local communities. The 35 voluntary fundraising committees of CMRI are the lifeblood of our community support, this year contributing over $1.6 million. The Christmas Catalogue provides an opportunity for fundraising through corporate Christmas cards, general cards and gifts which can be purchased throughout the year. It raises a steady income as well as raising awareness of CMRI’s work. Costs of raising these funds amounted to 24.5 cents in the dollar, a pleasing reduction on last year and well below the recommended 40 cents under the Charitable Fundraising Act. A detailed breakdown of all fundraising is shown on page 37. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 3 5 Funding of research operations a five year analysis 02/03 03/04 04/05 05/06 06/07 $000’s $000’s $000’s $000’s $000’s 6223 4480 2175 1 2233 53 15165 7474 6548 2435 – 1527 120 18104 4783 3121 2817 25 1195 124 12065 6931 8248 2871 – 3235 154 21439 8395 10892 2900 – 3283 177 25647 5176 3431 518 1780 34 189 384 180 160 36 50 30 886 313 10079 5086 5719 374 557 1955 25 187 296 213 201 37 41 24 1123 191 10953 7151 6148 419 773 2121 34 173 313 226 333 36 55 47 1122 406 12206 (141) 7388 430 671 2081 20 190 389 213 281 39 63 55 1089 501 13410 8029 7958 484 889 2557 30 157 350 324 206 89 84 102 1101 1382 15713 9934 1721 45 1766 575 1291 1866 990 302 1292 1480 34 1514 Revenue from all sources Net Proceeds from Fundraising Investment Income NH&MRC Grants Hospital Grants Other Grants Other Contributions TOTAL Expenditure on research operations Salaries – Research Salaries – Animal House Salaries – Other Laboratory Supplies Scientific Books and Journals Electricity, Gas and Water Repairs and Maintenance Research Travel and Conferences Insurance Telephones Postage and Freight Printing and Stationery Depreciation Other Expenses TOTAL EXPENDITURE RETAINED FUNDS Funds Applied to the Acquisition of Capital Equipment Buildings TOTAL 586 168 754 Balance sheet summary as at 30 June 2007 Current assets Non-current assets TOTAL ASSETS Current liabilities Non-current liabilities TOTAL LIABILITIES NET ASSETS 05/06 06/07 $000’s $000’s 5701 96915 102616 4262 106202 110464 4327 191 4518 98098 2817 221 3038 107426 76016 22082 98098 75410 32016 107426 Represented by: Reserves Retained funds TOTAL EQUITY 3 6 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Fundraising a five year analysis 02/03 03/04 04/05 05/06 06/07 $000’s $000’s $000’s $000’s $000’s 3556 374 242 453 3341 690 8656 4063 411 267 397 4265 770 10174 4021 467 223 484 1119 1028 7343 3775 277 197 447 3460 1264 9420 4018 403 298 402 4804 1193 11118 1406 240 104 683 2433 6223 1633 210 106 751 2700 7474 1622 241 120 576 2560 4783 1425 124 143 798 2490 6931 1890 105 187 541 2723 8395 Gross proceeds from fundraising Jeans for Genes Sale of merchandise Direct mail Committees Bequests Other TOTAL Total costs of fundraising Jeans for Genes Sale of merchandise Direct mail Other TOTAL NET SURPLUS FROM FUNDRAISING Revenue from all sources & allocation to research 2006/2007 } Revenue $25.65m Net Donations $8.40m Investments and Assets $107.43m Investment Income $10.89m { $8.40m $0.18m Admin, Insurances and Energy $1.86m { } Depreciation $1.10m $6.18m Other $0.18m { } Supplies $3.10m $9.32m { } { } { } Salaries $9.33m $1.57m Grants $6.18m Travel $0.32m Expenditure on Research $15.71m A detailed set of Audited Accounts is available on request or you can visit our website at www.cmri.com.au to view the full set of accounts. – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 3 7 Donations Thank you – F U N D R A I S I N G – } EVERY CONTRIBUTION HASTENS OUR JOURNEY. } } Committees Adelaide Committee of CMRI $833 Beecroft Committee of CMRI $23,192 Burbs Committee of CMRI $1,963 Can Can Committee of CMRI $2,000 Canberra Committee of CMRI $77,081 Canobolas Committee of CMRI $10,418 Cessnock Committee of CMRI $3,050 Gerringong Committee of CMRI $315,684 Gosford Committee of CMRI $10,643 Hills Committee of CMRI $57,769 Kangaroo Valley Committee of CMRI $11,790 Ku-ring-gai Committee of CMRI $27,092 Lakkariba Committee of CMRI $4,145 Lindfield Committee of CMRI $529 Maroota Committee of CMRI $21,466 Mudgee Committee of CMRI $11,206 Northern Beaches Committee of CMRI $745,696 Port Hacking Committee of CMRI $50,963 Putney Committee of CMRI $802 Quirindi Committee of CMRI $21,736 Racquet Committee of CMRI $24,357 Springtime Committee of CMRI $5,485 Strathfield Committee of CMRI $50,272 Tamworth Committee of CMRI $14,942 Taree Committee of CMRI $5,482 Thumbelina Committee of CMRI $31,084 Vaucluse Committee of CMRI $26,943 Wagga Wagga Committee of CMRI $47,263 Wamberal/Terrigal Committee of CMRI $3,501 TOTAL $1,607,387 Grants and bequests Grants Cancer Council NSW Cancer Institute NSW Cure Cancer Australia Foundation Millipore/Chemicon National Health and Medical Research Council Office for Science and Medical Research Ophthalmic Research Institute Australia Rett Syndrome Research Foundation Wellcome Trust (UK) TOTAL Estate of the late Phyllis Dawn Ronald Henry John Lynette Ann Ruth Winifred Charlotte Josephine Muriel Annie Allan Milton Eva Elizabeth Denise Linda Betty May Antoinette Hendrika Howard James Searle Marjorie Grace Jean Ellen Vevienne Therese Violet Winifred Doro William Brien Florence Christine Winifred Margarete Anneliese Elizabeth Jean Mary Henderson Simon Lena May Sybil Daphne Janine Haslewood Bruce Shirley Babette Valerie Elaine Grace Milbro Somers TOTAL $509,367 $847,600 $287,500 $23,203 $2,899,548 $1,156,752 $39,958 $79,338 $339,376 $6,182,642 BELLING $1,318.49 COLBY $40,000.00 DIGGLEMAN $2,000.00 FRASER $200.00 FREELAND $60,470.89 HAWKINS $131,240.21 HAYWARD $661,005.31 HENDERSON $25,000.00 HIGGINS $604,362.11 JEFFREY $46,088.07 JURRIAANS $5,722.66 LAKE $3,554.01 LAWN $150,000.00 LONG $217,971.77 MANNIX $1,000.00 MARSH $10,000.00 MARSH $1,000.00 MILLAR $192,000.00 PARFITT $1,570.00 PRAGER $272,932.35 RAMSAY $2,000,000.00 SHORTEN $2,000.00 STEVENS $24,501.97 SUTTON $53,546.55 TICKLE $110,000.00 TURNER $7,765.62 WALL $20,000.00 WHITE $25,000.00 WILSON $33,883.47 WOODHOUSE $100,000.00 $4,804,133.48 Supporters of goods and services in kind (Jeans for Genes) Jeans for Genes Badge and Merchandise Outlets Babies Galore, Banjo’s, BaySwiss, Best and Less, Big W, Charlie Brown, Crazy Clark, Domayne, Franklins, Gloria Jean’s Coffees, Glue Store, Go Lo, Harris Scarfe, Harvey Norman, HCF, Independent Jeans Retailers, Jeanswest, Joyce Mayne, Just Jeans, Lowes, MYER, Participating Pharmacies, Perfume Connection, Pharmacy Guild of Australia, Rebel Sport, Sizzler, Sunglass Hut, Terry White Chemists, The Warehouse, Toys R Us, Westpac. Celebrities who donated their jeans Tina Arena, Layne Beachley, Peter Brock, Smoky Dawson, Megan Gale, Rolf Harris, Natalie Imbruglia, Hugh Jackman, Nicole Kidman, Elle MacPherson, Dannii Minogue, Greg Norman, Harry Seidler, Steve Waugh, The Wiggles, ACDC (Angus and Malcolm Young). 3 8 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Artists who painted the jeans Elizabeth Barden, Ben Brown, Robyn Caughlan, Paul Dorin, Garry Fleming, Ernie Gerzabek, Nicholas Huxley, Marlene Jones, Anwen Keeling, Kathrin Longhurst, Andrew Mangelsdorf, Jos Myers, Nafisa Naomi, Paul Newton, Evert Ploeg, Robyn Ross. Major supporters APN Outdoor, ARIA, Arthouse Hotel, Art Studio, Aussie, Austar, Bathers Pavilion, Bel Parco Ristorante, Bernina, Big W, Blue Sydney, Bondi Surf School, Bottlemart, BMW, Brent Street Studios, BridgeClimb, Burwood Press, Canterbury, Cerrone, Charlie Brown, Coogee Sands Hotel and Apartments, Decorative Events, Design Lab, Dolphin Watch Jervis Bay, Domayne, Dreamworld, FitnessFirst, Forty One Restaurant, Harvey Norman, Hawaiian Airlines, Hayman, Huggies, Innoxa, Jeanswest, JetBoating Sydney Harbour, John Bevins Pty Ltd, Julio Valdes, Kimberly-Clark Australia, Lagoon Restaurant, Langham Hotel Melbourne, Lattouf, Leading Hotels of the World, Legion Limousines, Lindt of Switzerland, Mad Cortes, Manta, Maxum, Mineral Spa, Minus 5, MOKEM, MOR, Nova 96.9FM, Pacific Harbour Golf and Country Club, Palazzo Versace, Paper Bark Camp, Penrith White Water, Peter Lang, Pioneerstudios, Promina, Quest Cronulla Beach, Quest Wollongong, Royal Automobile Club of Australia, Rebel Sport, Sea World, Shop till you Drop, Sofitel Wentworth, Sunshades Eyewear, Swarovski, Sunglass Hut, Sydney Tower OzTrek, Taylor Made Travel, The Footy Show, Thomas Gallane Photography, Tomfoolery, Val Morgan, Vibe Hotels, Vietnam Airlines, Western Plains Zoo, Westfield, Westpac. Donations and contributions including Jeans for Genes ($1,000 and over) AMP Foundation AXA Australia AAMI AAMI Insurance ACOM Professional Pty Ltd AE Group AIG AMP Capital Investors Limited ANZ Bank – Operations, Technology & Shared Services ANZ Consumer Finance Ablec Electrical Wholesales Accenture Adamson, Ross Agueci, Jennie Air Road Foundation Aitken McLachlan Thorpe Lawyers Albury Wodonga Private Hospital Alcan Engineering Pty Ltd Algester Primary School All Hallows School All Saints Anglican School All Saints Grammar School Allens Arthur Robinson Allens Arthur Robinson NSW VIC NSW VIC NSW NSW VIC NSW $1,098 $2,999 $3,220 $2,684 $3,054 $1,422 $2,023 $1,098 VIC VIC NSW QLD NSW NSW NSW NSW NSW QLD QLD QLD QLD NSW VIC NSW $3,416 $2,022 $1,000 $1,799 $2,000 $3,165 $1,437 $1,892 $1,301 $1,066 $1,039 $3,203 $1,000 $1,420 $1,624 $20,137 B & D Australia B Braun Australia Pty Ltd BIG W Support Office BMW Group Australia BOC Limited Babcock & Brown Pty Ltd Bank of Queensland Bankstown Grammar School Bankstown Health Service Barnet, Joan M Barnsley Public School Beaconhills Christian College Belconnen Soccer Club Belmore Park Bendigo Bank – Lyric Building Best & Less Head Office Bevins, John Bevis, Jo-Anne Bio-Rad Laboratories Pty Ltd Bird, George NSW NSW NSW VIC NSW NSW QLD NSW NSW NSW NSW VIC ACT NSW VIC NSW NSW WA NSW QLD $1,179 $1,192 $137,731 $1,300 $5,966 $1,156 $1,144 $1,639 $2,053 $10,000 $1,116 $1,196 $1,173 $2,878 $4,923 $75,056 $2,000 $7,295 $1,843 $1,158 CA (Pacific) Pty Limited CAF Community Fund NSW NSW $1,234 $2,204 Amazing Human Body Ampelite Fibreglass Pty Ltd Anderson, Neil Aon Charitable Foundation Pty Ltd Arden Anglican School Armstrong, Jan Armstrong, Nigel Arthur Phillip High School Astra Zeneca Atwell Primary School Auburn Primary School Aussie Home Loans Austar Entertainment Austar Entertainment Pty Ltd Austin Hospital Australia Post OH & S Department Australian Discount Retail (Trading) Pty Ltd Australian Federal Police Australian Hotels Association Australian Submarine Corporation Pty Ltd Authentic Trademarks Avant Insurance Ave Maria College Avis Australia Aviva Australia NSW VIC NSW VIC NSW NSW NSW NSW NSW WA VIC NSW NSW QLD VIC NSW NSW ACT NSW SA NSW NSW VIC NSW VIC $2,317 $1,902 $1,000 $5,000 $2,900 $1,200 $1,000 $1,608 $1,034 $1,075 $1,071 $30,000 $3,919 $2,633 $2,090 $1,711 $108,226 $1,308 $1,623 $1,341 $1,035 $2,500 $1,316 $1,531 $1,131 Blacktown City Council Blacktown RSL Blacktown Workers Club Blake Dawson Waldron Blooms the Chemist, Penrith Plaza Blue Mountains Grammar School Boart Longyear Pty Ltd Bohm, Martin Boo, Priscilla Boronia Heights Primary School Bramble, T and D Brooklyn Group Brunsdon AM, Norman K Bryan, Joan M Built Environs Burrows, Valma Burwood Press Butler, EG Butler Primary School NSW NSW NSW NSW NSW NSW SA NSW VIC VIC NSW NSW NSW NSW SA NSW NSW NSW WA $1,646 $6,855 $1,303 $1,422 $1,415 $1,072 $1,012 $1,000 $1,552 $1,097 $5,000 $4,177 $2,085 $4,000 $1,551 $1,110 $30,644 $3,000 $1,174 CBI Constructors Pty Ltd Cadbury Schweppes – C M R I NSW VIC 2 0 0 6 / 2 0 0 7 $2,994 $1,034 A N N U A L {A {B {C R E P O R T – 3 9 D} E} F} G} 4 0 – C M R I Camden High School Canberra Girls’ Grammar School Canon Australia Canterbury College – Junior School Canterbury-Hurlstone Park RSL Womens Auxiliary Cardinal Health Carey Baptist Grammar School Carlson Wagonlit Caroline Chisholm Catholic College Castle Cove Primary School Castle Hill Public School Castle Hill Rotaract Club Catherine McAuley Westmead Cecchele, Giovanna Cecil Hills High School Cement Australia Centennial Angus Place Central Coast Area Health Services Central Coast Creative Craft Group Inc Centrelink International Services Centrelink Nowra Challenger Financial Services Group Channel 7 Chester Hill RSL & Bowling Club Co Operative Limited Children’s Hospital Westmead NSW ACT NSW QLD $1,000 $1,685 $1,106 $3,287 NSW NSW VIC NSW VIC NSW NSW NSW NSW WA NSW QLD NSW NSW NSW TAS NSW NSW NSW $1,000 $1,882 $1,901 $2,500 $1,017 $1,395 $1,262 $1,500 $1,712 $1,080 $1,289 $1,320 $1,200 $1,706 $2,500 $1,502 $1,074 $1,647 $7,800 NSW NSW $3,000 $1,331 NSW $1,000 NSW NT ACT $2,265 $1,120 $1,159 ACT VIC $1,976 $1,125 ACT $1,200 NSW $1,022 NSW VIC NSW $25,000 $3,264 $1,700 NSW NSW NSW NSW $2,090 $1,190 $1,004 $20,000 FM Insurance Company Ltd FSL Systems Fairfax AO, James Farrell, John Federal Court of Australia Feehan Communications First Data International Fishers Stores Consolidated Flannery’s Pharmacy Flight Centre Limited VIC WA NSW NSW NSW NSW NSW VIC NSW QLD $1,106 $1,897 $70,000 $1,500 $1,321 $1,140 $2,078 $4,360 $1,207 $1,345 Gambier City Pharmacy Georges River Art Group Gilgandra Motors Sales & Service Girraween High School Gladstone Park Primary School SA NSW NSW NSW VIC $1,087 $2,000 $2,684 $1,192 $1,050 DSC Personnel Dana Automotive Systems Group Australia – Yennora Darwin International Airport Department of Defence Department of Finance and Administration Department of Human Services Department of Industry Tourism & Resources Department of Infrastructure Planning and Natural Resource Earle Page College – University of New England Eastern Health – Box Hill Hospital Eastwood and District Orchid Society Einfeld Symonds Vince Chartered Accountants Elanora Country Club Elderslie High School Energy Australia 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Church, Lynne M Churchlands Senior High School Circular Quay Railway Station Civic Hotel Clare Catholic High School Clayton Utz (Sydney) Clayton Utz Foundation Cleaver, Georgina Clorox Australia Pty Limited Coles Supermarket Coloplast Pty Ltd Commander Australia Ltd Commonwealth Bank of Australia Coorparoo RSL Club Corbett Research Pty Ltd Corkhill, William Cornerstone College Cornetts IGA Supermarket Cospak International Pty Ltd Country Energy Countrylink Management Coventrys Creer Property Croll, Judith Crown Scientific Pty Ltd Cummins Engine Co NSW WA NSW NSW NSW NSW NSW NSW NSW SA VIC NSW NSW QLD NSW NSW SA QLD NSW NSW NSW WA NSW NSW NSW VIC $10,000 $1,227 $6,740 $1,251 $1,139 $2,576 $4,661 $1,025 $12,669 $1,139 $2,078 $1,536 $1,106 $3,746 $29,500 $5,000 $1,060 $1,753 $2,497 $1,542 $2,424 $1,455 $3,349 $1,000 $1,275 $8,364 ACT NSW QLD NSW NSW QLD NSW $1,968 $1,000 $1,000 $6,589 $50,000 $1,007 $1,060 NSW QLD NSW $117,349 $1,300 $5,533 Energy Australia Employees Children’s Appeal Enertrade Epping Railway Station Ernest & Piroska Major Foundation Eventide Homes (NSW) Everyday Hero Pty Ltd Excelsior Public School NSW QLD NSW NSW NSW QLD NSW $3,000 $1,019 $1,408 $42,858 $20,000 $2,069 $1,001 Foodland Superfresh Bordertown Forster, Carolyn Franklins Support Office Frankston High School Fraser, Jeannie Ross Fred Hosking Pty Ltd Frederick Irwin Anglican School Freedman, Clarette Freeman Catholic College French, Rae SA ACT NSW VIC NSW NSW WA NSW NSW NSW $1,025 $1,272 $50,000 $1,253 $1,000 $4,009 $2,300 $1,000 $1,586 $15,000 VIC VIC $1,200 $1,023 NSW NSW $2,000 $2,825 Department of the Environment & Water Resources Devereaux, Maureen Discount Jeans Donovan, Tricia Dowling, Aileen Downlands College Doyle, F P Drive for Charity – M4, M5 and Eastern Distributor Duffie, Mark Dunlop, Ian Gladstone Park Secondary College Glaxo Smith Kline Glendonbrook Wines & Daly Smith Corporation Gloria Jean’s Coffees Head Office Gold Creek Primary School ACT Gollan, Judith NSW Goodwill Charity Card Shop NSW Gordon Institute of TAFE VIC Gordon Railway Station NSW Goulburn Valley Grammar School VIC Goulburn Valley Health – Children’s Ward VIC $1,564 $2,000 $20,109 $1,196 $2,192 $1,268 $1,200 Governor Philip King Public School Grant Thornton Green, JH Gregory, Hal & Diana Guildford Grammar School Guildford Leagues Club NSW QLD NSW NSW WA NSW $1,457 $1,864 $1,100 $10,217 $2,116 $1,651 HCF Head Office HSBC Bank Australia Ltd Haileybury College Hale, Alison Hale, Jean Hall, Anthony Hannan, Kieren Hansford, Richard Hare and Forbes Machinery House Harris Scarfe Australia Pty Ltd H/O Harristown State High School Harwood Andrews Lawyers Hatch, BC Hatch Associates Pty Ltd Hawkesbury High School NSW NSW VIC NSW NSW QLD NSW NSW NSW SA QLD VIC NSW WA NSW $12,508 $2,217 $1,742 $5,065 $6,045 $18,350 $1,361 $4,831 $5,000 $8,663 $1,032 $1,107 $2,000 $1,158 $1,663 Heath, AE Heidelberg Graphic Equipment Hicks, Ian & Lea Hind, David & Jo Hodgkinson & McInnes Pappas Hornsby Girls High School Hornsby Railway Station Hotsource Howchin, Jean Howell, Donna Hume Building Society Hunter Hall Charitable Giving Program Hunter Valley Grammar School Hurstville Public School Hutton, DG NSW VIC NSW NSW NSW NSW NSW NSW NSW NSW NSW NSW NSW NSW NSW $1,000 $1,000 $10,580 $4,000 $1,195 $2,270 $1,640 $1,684 $10,000 $1,266 $1,372 $35,927 $1,260 $1,640 $1,000 IVECO Trucks Ian McNair Charitable Foundation Ltd Ignatius Park College Ingleburn RSL Club Ivanhoe Grammar School – The Ridgeway Secondary J P Morgan Jadin Chemist Group – Big Box Chemist James Hardie Building – Social Club James Ruse Agricultural High School Jazz in the Junction Jeans West – Head Office Jenkins, Alan VIC NSW QLD NSW $1,134 $2,000 $1,172 $1,574 NSW NSW QLD NSW $1,000 $2,691 $3,084 $2,400 VIC NSW QLD NSW NSW QLD VIC ACT $1,033 $3,012 $1,449 $3,114 $1,247 $25,044 $45,741 $2,000 Jennings, Valda P John Bevins Pty Limited John Paul College John Sample Group Pty Ltd John Wollaston Anglican Community School Jolly & Family, Alan & Ann Jones, Oliver & Paula Jones, Wayne Jordan, GV Judith Hyam Memorial Trust Fund for Cancer Research Just Jeans Head Office WA NSW USA NSW NSW $1,171 $3,000 $2,569 $1,100 $1,500 NSW VIC $154,106 $68,141 KPMG K-Mart KCA Warwick Farm Social Club Keeghan, Gerard Kellerman, GM Kengreen Consulting Pty Ltd Quantity Surveyors Kilikanoon Clare Valley Kimberley Park Primary School NSW VIC NSW VIC NSW $3,147 $1,331 $1,600 $2,000 $3,000 NSW NSW QLD $4,355 $2,500 $1,179 Lalor Secondary College Lane Cove Public School Le Page Primary School Leighton Holdings Pty Limited Lions Club of Oatley Liverpool City Council Locker Room – Telstra Dome VIC NSW VIC NSW NSW NSW VIC $1,034 $1,237 $1,034 $6,796 $1,520 $1,000 $1,855 MFR Financial Planners Australia Pty Ltd MLC School MYER Community Fund Mackisack, Joan Macquarie Bank Foundation Macquarie Bank Ltd – Banking & Securities Division Macquarie Financial Services Group Maitland Grossmann High School VIC NSW VIC NSW NSW $1,115 $2,117 $78,377 $4,584 $1,244 NSW NSW NSW $1,000 $1,351 $1,662 Kimberly-Clark Australia Pty Ltd Kimberly-Clark Australia Pty Ltd Kincoppal-Rose Bay School of the Sacred Heart Kingsford Hotel Kinross Wolaroi Primary School Knox Grammar School Kolak, Nada Krispy Kreme NSW SA $64,982 $2,073 NSW SA NSW NSW NSW NSW $1,160 $1,003 $1,140 $2,000 $3,740 $1,682 Locksmiths Supply Company Lowe, Michael Lowes Manhattan Head Office Lubrizol International Inc Lumley General Insurance Ltd Lycopodium Engineering Pty Ltd VIC NSW NSW NSW NSW WA $2,156 $2,000 $21,413 $1,090 $1,976 $11,016 Man Investment Australia Ltd Maranatha Christian College March, Rhonda Marion McCosker Martin Place Marymount Primary School Mater Mothers Hospital McAdams, Ian McCarthy Catholic College NSW WA NSW NSW NSW QLD QLD NSW NSW $4,295 $1,038 $2,470 $2,500 $8,605 $1,103 $1,380 $5,000 $1,302 – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L {H { I J {K {L {M R E P O R T – 4 1 N} O} P} Q } R S} 4 2 – C M R I McKernan, Judith McKinnon Direct Medicare Australia Medicare Australia Medicare Australia Social Club Medtronic Australasia Pty Ltd Melbourne East Group Training Melbourne Girls Grammar Merrill Lynch Metricon Homes Qld Pty Ltd Metropolitan Ambulance Service NSW NSW WA NSW NSW NSW VIC VIC NSW QLD VIC $1,000 $8,900 $2,703 $4,819 $1,484 $1,007 $1,598 $1,889 $5,305 $1,087 $3,535 Millard, Anita Minter Ellison Lawyers Monckton, EM Montgrove College Mortgage Choice Morton, Patricia Motors Pty Ltd Mount Eliza North Primary School Mowbray College Munno Para Foodland Musashi Pty Ltd NSW NSW NSW NSW NSW NSW TAS VIC VIC SA VIC $1,000 $1,382 $1,000 $1,500 $1,538 $1,026 $1,200 $1,069 $1,952 $1,049 $1,247 NSW Business Chamber NSW Businesslink NSW Teachers Credit Union Nagle College Narangba Valley State High School Narellan Vale Public School Needs, K & L Nell & Hermon Slade Trust Nepean Hospital Volunteers Gift Shop Neuhaus, Gillian C Neutral Bay Public School NSW NSW NSW VIC QLD NSW NSW NSW NSW NSW NSW $1,601 $1,327 $2,568 $1,378 $1,056 $1,638 $1,072 $1,000 $1,255 $4,000 $1,287 Newington College News Ltd Niagara Park Public School Noosaville State School North Bondi RSL Northline Note Printing Australia – Occupational Health Centre Nuplex Industries (Aust) Pty Ltd Nutricia Australia Pty Ltd NSW NSW NSW QLD NSW NSW $2,157 $1,882 $1,453 $1,099 $1,519 $1,798 VIC NSW NSW $1,396 $1,586 $1,305 O’Connor, Kevin & Betty O’Neill, Helen Oatlands Golf Club Associates Office of Fair Trading Office of State Revenue – State Department Recovery NSW NSW NSW NSW $1,600 $1,000 $4,360 $2,718 VIC $15,000 NSW $3,561 Olympic Hotel Open Training & Education Network – Social Committee Orange High School Ord Minnett Group Limited Orme, WJ and EN NSW NSW NSW NSW $1,480 $1,056 $10,725 $5,000 Pacific Brands Hosiery Group Parramatta City Council Parramatta Leagues Club Pasadena Foodland Pendragon Penleigh & Essendon Grammar School Penrhos College Penrith Anglican College Perfection Badges Perpetual Trustees Australia Limited Peter Sheahan Pty Ltd Peters, Russell Pfizer Australia Pty Ltd VIC NSW NSW SA NSW VIC WA NSW NSW NSW NSW VIC NSW $1,413 $2,241 $1,419 $1,010 $24,047 $2,904 $1,445 $1,325 $6,720 $1,500 $1,000 $1,000 $2,112 Philps, Jennifer Picton High School Pitt Street Mall Pittwater High School Pittwater RSL Powerlink Queensland Prairiewood High School Presbyterian Ladies’ College, Sydney Preston Group Promina Group Limited Public Trustee Pymble Ladies College NSW NSW NSW NSW NSW QLD NSW NSW NSW NSW NSW NSW $2,031 $1,128 $4,266 $1,033 $2,780 $1,579 $1,054 $1,100 $21,370 $151,271 $1,527 $1,947 QBE Insurance Group Limited Queen Victoria Building Quakers Hill High School R F Entertainment & Promotions R K Thomas Pty Ltd RAAF School of Technical Training – Navy Admin Rabobank Rail Corporation Ramsden, Elizabeth Ravenswood School for Girls Ray White Double Bay Group Raytheon Australia Pty Ltd Rebel Sport Head Office Reddel, JD NSW NSW NSW NSW QLD $15,000 $2,171 $1,449 $1,000 $2,396 NSW NSW NSW NSW NSW NSW QLD NSW NSW $1,000 $1,699 $2,973 $8,000 $5,444 $2,000 $1,371 $10,197 $15,000 Redlands Preparatory School Regional Breakthroughs River Gum Primary School Riverside Girls High School Robinson, Ian Roche Diagnostics Pty Ltd Rotary Club of Parkes Rotary Club of Turramurra Roxburgh, Roy Royal Automobile Club of Australia Royal Darwin Hospital Royal Oak Hotel Ryde Secondary College Ryde-Eastwood Leagues Club NSW SA VIC NSW NSW NSW NSW NSW NSW NSW NT VIC NSW NSW $1,518 $1,900 $1,057 $1,016 $1,650 $1,140 $6,000 $1,234 $1,000 $8,323 $1,099 $1,440 $1,083 $1,804 SCEGGS Darlinghurst Saha International Salmon, JH & D Samies Girl NSW VIC NSW QLD $1,033 $1,708 $1,000 $1,095 Sanders Jannali First National Real Estate Scotch College Adelaide Scott Motor Group Servite College NSW SA NSW WA $1,280 $1,451 $1,090 $1,460 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – Seven Hills Toongabbie RSL Club Seven Network Sheriff’s Office Sizzler Head Office Skevington, Clement Skinner, Eric Slack, Judith Smith, Alan & Jennifer Souter, Shirley M South East Queensland Water Specialist Dental Suite Spotless Services Limited Spruson & Ferguson St Angela’s Primary Catholic School St Charbel’s College St George School St Helena Secondary School St Ives Real Estate St James Station and Hyde Park St John’s Primary School St Joseph’s College St Joseph’s College St Lucia News St Luke’s Anglican School St Madeleine’s Catholic Primary School St Mark’s Primary School NSW NSW NSW QLD NSW NSW NSW NSW NSW QLD NSW VIC NSW NSW NSW NSW VIC NSW NSW NSW VIC NSW QLD QLD NSW NSW $1,447 $3,000 $1,000 $3,112 $4,300 $1,560 $2,200 $5,063 $1,000 $1,448 $1,912 $1,026 $2,500 $1,341 $3,397 $1,000 $1,073 $1,693 $5,356 $1,111 $1,217 $1,611 $1,715 $1,220 $1,177 $1,083 Tara Anglican School For Girls Taree High School Target Tattersall, Edna TechFlare Solutions Tenix Group The Chef’s Toolbox The Good Guys The Hills Grammar School The J & G and JB Bedwell Foundations The Kings School The Knox School The McGrath Motor Group The Moore Family Philanthropic Foundation Limited The Perfume Connection The Public Trustee of QLD The RA Gale Foundation The Riviera Group The Tweed Heads Hospital NSW NSW NSW NSW NSW NSW NSW WA NSW NSW NSW VIC NSW $1,026 $4,118 $1,020 $2,500 $2,200 $1,472 $2,966 $1,090 $2,449 $13,382 $1,466 $1,164 $2,954 NSW QLD QLD NSW QLD NSW $2,000 $4,472 $1,599 $6,000 $1,359 $1,127 UFS Dispensary UBS University of Western Sydney – UWS Connect VIC NSW $1,520 $1,450 NSW $1,220 Wattyl Australia Pty Limited Wellington Primary School Westfield Design & Construction Pty Limited Westfield Shopping Centre, Penrith Westfield Shopping Centre, East Gardens Westfield Shopping Centre, Chatswood Westfield Shopping Centre, Miranda Westfield Shopping Centre, Parramatta Westfields Sports High School Westmead Railway Station Westpac Banking Corporation, Sydney Westpac Banking Corporation, Parramatta Westpac Banking Corporation NSW NSW $4,365 $1,060 NSW NSW NSW NSW NSW NSW NSW NSW NSW NSW WA $1,084 $6,266 $1,420 $1,248 $3,117 $2,928 $1,868 $2,006 $6,221 $1,838 $2,055 } St Paul’s Senior School St Paul’s Primary School St Peter Apostle Primary School St Philip’s College – Griffiths House St Spyridon College St Ursula’s College St Vincents & Mater Health Sydney St Andrew’s Primary School Standard Communications Pty Ltd Star City Casino Starkey Australia Pty Ltd State Revenue Office State Street Australia Limited Stimson, Shirley J Storch, Daniel Strathfield Girls High School Sule College Girls High School Summer Hill Public School Sunglass Hut Head Office Sutherland District Trade Union Club Swales, David Sydney Boys High School Sydney Grammar School St Ives Preparatory Sydney Ultrasound for Women QLD NSW VIC NT NSW NSW NSW VIC NSW NSW NSW VIC NSW NSW NSW NSW NSW NSW NSW NSW VIC NSW $1,551 $1,730 $2,277 $1,330 $1,400 $3,430 $1,852 $1,214 $2,433 $8,000 $1,110 $1,691 $2,271 $1,200 $2,000 $1,340 $1,252 $1,521 $6,538 $1,362 $2,000 $2,468 NSW NSW $2,416 $4,635 Thomas, Fred G Thomas & Coffey Tintern Anglican Girls Grammar School Titley, MG & EM Toll Priority – DX Solutions Toorak College Toowoomba State High School Tower Australia Limited Toyota Financial Services Toys R Us Store Support Office Tranby College Treasury of Craft Trinity Grammar Preparatory School Trivett Classic Trivett Classic BMW Trust Company Ltd Trust Company of Australia Limited Tully, Brooke Tura Beach Country Club NSW NSW VIC NSW NSW VIC QLD NSW NSW NSW WA NSW NSW NSW NSW VIC NSW VIC NSW $1,000 $6,110 $1,359 $1,250 $1,384 $1,371 $2,563 $1,621 $29,770 $9,087 $1,888 $5,015 $1,878 $2,272 $6,800 $5,000 $5,500 $1,159 $1,230 Upper Coomera State College Urangan State High School Victoria Hotel QLD QLD NT $1,341 $1,007 $8,500 Westpac Matching Gifts Program Winters, Katrina Woolooware High School Woolworths Limited WorkCover QLD Worroll, Shirley Worsley, B Wrighter, Edward M Wynyard Park Wyong Shire Council – Social Club Yeatman, KA & OM Young Presidents’ Organization de Vries Tayeh NSW NSW NSW NSW QLD WA NSW NSW NSW NSW NSW SA NSW $16,206 $1,302 $2,160 $8,898 $2,907 $2,788 $2,750 $1,000 $5,610 $1,688 $2,250 $1,000 $2,110 {T {U V {W Y and of course enormous thanks go to our Jeans for Genes genies, thousands Australia wide :) – C M R I 2 0 0 6 / 2 0 0 7 A N N U A L R E P O R T – 4 3 How you can help Children of the future will benefit from your support. Call us now to help make a difference on freecall 1800 GENIES / 1800 436 437 Provide for the CMRI in your will – suggested form of wording: ‘I bequeath to the Children’s Medical Research Institute ABN 47 002 684 737 the sum of $ free of all duties for the purposes of the said Institute and the receipt of the Secretary or Treasurer of the Institute shall be sufficient discharge of the same.’ and/or make a donation now: I/We wish to make a donation of Payment is attached: $ cheque to the Institute. money order credit card Card number Expiry date / Name on card Your name Signature Address Postcode Email Telephone Facsimile Photocopy and fill out this coupon, and return it to us with your donation. More information: I would like the opportunity to discuss the work of the CMRI with a representative of the Institute. Please send me more information on making a bequest. Please put me on the mailing list to receive the CMRI’s quarterly newsletter, Under the Microscope. Children’s Medical Research Institute ACN 002 684 737 Postal address: Street address: Telephone: Facsimile: Email: Internet address: 4 4 – C M R I 2 0 0 6 / 2 0 0 7 Locked Bag 23 Wentworthville NSW 2145 Australia 214 Hawkesbury Road Westmead NSW 2145 Australia 02 9687 2800 Freecall: 1800 GENIES / 1800 436 437 02 9687 2120 info@cmri.com.au www.cmri.com.au and www.jeans4genes.com.au A N N U A L R E P O R T – Designed by The Glasshouse, Sydney www.theglasshouse.com.au hope cmri.com.au 214 Hawkesbury Road Westmead NSW 2145 Australia